Message from Zan Guerry
Chairman and CEO of Chattem
Lou Holtz said God put eyes in the front of our head so we would look
forward, not backward. Chattem certainly is a forward looking company, anxious
for more growth, and almost all of this annual report is focused on the future.
However, given the richness of our heritage, I think a brief look back at the
century and the last decade is appropriate.
HOW DOES A COMPANY SURVIVE A CENTURY
Very few CEO's can even address the issue of how their company lasted a
full century. In fact, Chattem has now existed for 120 years. In order to
survive and prosper for that long, clearly a company must have a sound business
strategy. Our strategy of leadership in the health and beauty markets in which
we compete, unique products and strong advertising support has stood the test of
time.
A company must also be blessed with an enthusiastic, hard working,
loyal workforce. I will put Chattem's employees against anyone based on these
criteria. Further, a company must have a little good fortune. Chattem's growth
has come almost exclusively from making acquisitions and then growing the
business through advertising and line extensions. We must have other companies
offer us brands to acquire at reasonable prices to be successful in executing
this strategy, and generally we have been fortunate in having good acquisition
candidates presented to us.
Finally, and most important, it occurs to me that the primary reason a
company thrives for over a century is about CHARACTER. Character is interesting
in that we can look at people and say they have character, for example, Colin
Powell, Arnold Palmer, Mother Teresa, among others, but we could spend this
whole report defining what character means. My definition of character for
Chattem, which its leaders, directors and employees have long demonstrated, is
as follows: Character means all for one and one for all. We work as a team and
large individual egos simply do not exist. We operate from a simple philosophy
of "Do what is right, do your best and treat others as you wish to be treated".
We live this not only in our lives at Chattem, but in our community. It is a
great pleasure to lead a company that has character.
THE MAGNIFICENT DECADE
Clearly Chattem has done many great things in its history, but in the
last decade is when Chattem moved to a whole new level. Interestingly, it
started with FLEXALL and Joe Namath. Although we have had many marketing
successes, FLEXALL put the confidence in us that we could compete with the
best. Led by FLEXALL, Chattem's earnings soared at a 37% compound rate for
three years in the early 90s and our stock price increased 400% during the
same period.
In 1993 and 1994 we were tested by strong competition, the loss of a
key chemicals customer and a lack of acquisitions. These were tough
rebuilding years. However, starting in 1995, we went on an unprecedented
growth streak in which sales tripled from $100 million to nearly $300 million
in 1999, a compound growth rate of 31%. Earnings per share before
extraordinary items and product divestitures grew even faster from $.32 in
1995 to $2.25 last year, a compound rate of 63%. These numbers clearly allow
me to call the 1990's Chattem's magnificent decade.
1999 -- A REVIEW
1999 was an enigmatic year. For the last two years, I have written to
you that Chattem had the best years in our history. I easily could again make
that claim, as we had by far the largest increase in earnings per share in
history in both an absolute and a percentage basis. For the year, earnings per
share before extraordinary items and product divestiture increased by 80%, or
$1.00, from $1.25 to $2.25.
In addition, our results are based on the performance of our brands and
we had a number of significant successes. MUDD increased 40% led by updated
packaging and the new MUDD Self-Heating Skin Cleanser. PHISODERM increased 25%
due to a successful new acne cleanser. GOLD BOND continued its strong growth
increasing 27% led by the new antibiotic ointment, a full year of GOLD BOND
medicated lotion and growth in the powder, foot and cream products. HERPECIN-L
also had an outstanding year, increasing more than 25%. Also, many of our strong
profit brands, including our topical analgesics, menstrual products and BAN, had
solid years. Thus, 1999 had a great number of product successes.
There were two areas of disappointment, however, which diminished
the successes of the year. From a brand perspective, we encountered
significant competition against DEXATRIM and SUNSOURCE, which resulted in
both being about 25% below expectations. For DEXATRIM, the major new
competition came from Metabolife-Registered Trademark- and new prescription
products. For SUNSOURCE, there continued to be new competition in the herbal
markets from a number of sources including major pharmaceutical companies.
The other area of disappointment was our stock price. At the beginning
of the year we considered selling approximately $100 million of stock to
strengthen our balance sheet and provide growth capital. The U.S. capital
market's job is to allocate capital to successful companies. Given Chattem's
success it is amazing and extremely discouraging that we can produce a five
year 63% compound growth in earnings per share and be rewarded with a P/E of
less than 10, given the extremely high P/Es of many stocks. We can still make
acquisitions using the high yield and bank debt markets, but it may be
preferable in some circumstances to use proceeds from the sale of equity.
FISCAL 2000 OUTLOOK*
After five years of dynamic growth in earnings per share, 2000 appears
to be one of more modest growth, in the 7-10% range. This temporary slower
growth rate is due to the absence of any acquisitions in the last twelve
months, continued competition, as mentioned, for DEXATRIM and SUNSOURCE,
expected new competition in the deodorant market and the need to support with
investment spending a number of new products.
Our goal for 2000 and beyond is to return quickly to superior earnings
growth rates. To accomplish this, we will first aggressively return to an
acquisition mode. In 1999 we felt we needed to assimilate our recent
acquisitions. This has been accomplished and we are presently aggressively
looking for brands that fit our strategy.
Second, we have some very exciting new product launches. We have not
budgeted strong numbers for any of these, but if they prove successful, we could
add meaningful growth to earnings. The four most promising product launches
which will receive the bulk of our investment spending are BAN Naturals,
DEXATRIM Natural, PHISODERM Blemish Patch and GOLD BOND Sensitive
2
Skin Lotion. Later in this report you can read in detail about these exciting
launches. I will simply say that all four have very high market research scores
which indicate each could be a multi-million dollar idea.
In addition to these four big launches, we have several other important
new products. SUNSOURCE is currently introducing OMNIGEST EZ, which is a seven
enzyme product to help digestion. America is currently hooked on antacids or
acid blockers to cover the symptoms of poor digestion. OMNIGEST EZ treats the
problem naturally. Also, SUNSOURCE is introducing NEW PHASE, a phytoestrogen
product for menopause.
BULLFROG is introducing Sports Spray, which is simply the best
sunblock product on the market, Sparkle Block for kids and AgeProof for
seniors. In addition, late year 1999 launches, FLEXALL QUIK GEL, MUDD
Self-Heating and PHISODERM Acne, will continue to receive support.
STRATEGIC PERSPECTIVE*
To follow a decade as outstanding as the 1990's is a daunting task.
However, led by our proven acquisition ability, the new products mentioned above
and our marketing skills, we are committed to becoming a $500 million plus
company in the coming decade.
Our managers, directors and employees are all enthusiastic about
opportunities for further growth. We are committed to bringing to you, our
shareholders, another outstanding decade of growth in sales and earnings which
we hope will also result in a higher stock price.
*The statements in these sections constitute "forward looking
statements" within the meaning of the Private Securities Litigation Reform Act
of 1995.
Metabolife-Registered Trademark-is a registered trademark of
Metabolife International, Inc.
3
CHATTEM CONSUMER PRODUCTS
DOMESTIC PRODUCT OVERVIEW
OTC HEALTH CARE PRODUCTS
MEDICATED SKIN CARE PRODUCTS
GOLD BOND is America's number one brand of medicated powder in the $41 million
medicated powder category. With its unique positioning and strong brand equity,
GOLD BOND has successfully extended into other skin care segments. For example,
GOLD BOND cream continues to be one of the fastest growing brands in the $207
million anti-itch cream market. In addition, GOLD BOND Foot Powder and GOLD BOND
Cornstarch Plus Medicated Baby Powder have added incremental sales to the
franchise since their launch in 1997. In the summer of 1998, GOLD BOND entered
the $1 billion hand and body lotion category with GOLD BOND Medicated Body
Lotion which has quickly become a major product in the therapeutic anti-itch
segment. During 2000, GOLD BOND is expanding its presence in the lotion category
with the launch of GOLD BOND Fragrance Free Medicated Body Lotion, a product
uniquely formulated to soothe and protect itchy skin for consumers that desire a
fragrance free formula or have sensitive skin. GOLD BOND Triple Action
Antibiotic Ointment was launched in early 1999 in the $190 million antibiotic
ointment category. Looking to 2000, GOLD BOND will continue to benefit from
record levels of advertising and consumer promotion support.
TOPICAL ANALGESICS
With the acquisition of brands from Thompson Medical in late 1998, the Company
is the overwhelming leader in the $215 million topical analgesic category with
its FLEXALL, ICY HOT, ASPERCREME, SPORTSCREME, CAPZASIN and ARTHRITIS HOT
brands.
Positioned as "full speed relief for tough pain", FLEXALL is an aloe based
topical analgesic that provides fast relief for arthritis, joint and muscle
pain. The brand's current product line includes Original Vitamin E Enriched,
Maximum Strength, Ultra Plus and the recently launched QUIK GEL. FLEXALL QUIK
GEL is formulated to provide fast pain relief without the greasy mess inherent
in old-fashioned pain rubs. FLEXALL enjoys extensive advertising support
featuring NFL Hall of Famer, Joe Montana.
ICY HOT offers the most complete product form line-up in the category with a
cream, a balm and the unique CHILL STICK. Heavy television advertising
communicating the brand's distinctive "icy to dull the pain, hot to relax it
away" positioning continues to generate consistent retail sales growth.
ASPERCREME provides clinically proven relief for arthritis pain. The brand's
odor free formula has particularly strong appeal among women over fifty that are
suffering from arthritis.
SPORTSCREME is targeted at the serious athlete and "weekend warrior" and
provides relief from muscle aches and strains. The product has an appealing,
fresh scent. For the year 2000, SPORTSCREME will benefit from increased
advertising reach as the brand expands beyond the historical TV cable only media
source.
CAPZASIN-P and CAPZASIN-HP contain the active ingredient doctors recommend most.
During 2000 CAPZASIN will be supported by an unprecedented national radio
advertising plan.
The ARTHRITIS HOT brand provides pain relief for consumers looking for a value
price.
In addition, the Company competes in the $65 million internal irritation segment
of the topical oral analgesic category with BENZODENT. BENZODENT is the only
product specifically positioned to be applied directly to dentures to relieve
pain. The product contains the maximum amount of benzocaine allowed in the
category and is widely recommended by dentists. Marketing efforts are focused on
4
providing samples to consumers when they are initially fitted for dentures, the
point of entry for the category.
INTERNAL ANALGESICS
The Company competes in the $67 million menstrual pain relief category with its
PAMPRIN and PREMSYN PMS brands. NORWICH Aspirin competes in the general
analgesic category.
PAMPRIN, the number two brand in the category, is a combination drug
specifically for relief of menstrual symptoms. Unlike ordinary pain relievers,
Multi-Symptom PAMPRIN contains three active ingredients to effectively relieve
multiple menstrual discomforts. Maximum Cramp Relief PAMPRIN contains two active
pain medications to relieve cramps, headaches and backaches. Maximum Strength
PREMSYN PMS, the third largest brand in the category, effectively relieves the
physical and emotional symptoms of PMS. PAMPRIN and PREMSYN PMS are supported
with a combination of television, radio and print advertising as well as point
of entry sampling to teens.
NORWICH, a high quality, reasonably priced aspirin, complements the other OTC
pharmaceuticals of the division. Sales and marketing support is principally
focused in the northeast, midwest and west coast.
LIP CARE
The Company competes in the $57 million cold sore market with HERPECIN-L. Retail
sales have increased by over 30% since 1997 as a result of a reformulation of
the stick, the introduction of the jar and the execution of a national radio
advertising campaign. For 2000, radio advertising has been increased to maximize
support for the brand during the critical cough/cold season.
APPETITE SUPPRESSANT
DEXATRIM is a line of appetite suppressants which was acquired in December 1998.
DEXATRIM is available in four different formulas including gelcaps, which were
introduced in early 1999. The brand is supported through strong television
advertising focusing on the safety and efficacy of DEXATRIM as a diet aid. In
2000 DEXATRIM will enter the explosive herbal diet aid category with DEXATRIM
Natural. DEXATRIM Natural is a drug-free, all natural diet aid with special dual
action that curbs appetite and helps the body burn fat and calories. DEXATRIM
and DEXATRIM Natural will be supported through high levels of television
advertising in 2000.
DIETARY SUPPLEMENTS
The Company competes in the U.S. nutritional supplement category with its
SUNSOURCE line which includes GARLIQUE, REJUVEX, PROPALMEX, HARMONEX,
MELATONEX, REPOSE and ECHINEX. These products are distributed primarily
through the food, drug and mass merchandiser trade channels.
GARLIQUE holds a 16% share of the $80 million garlic category, and is the leader
among branded garlic extract products. Clinical research on the benefits of
garlic support the position of GARLIQUE as a dietary supplement for good
cardiovascular health. Scientists have identified allicin as an active
ingredient in garlic, and the garlic selected for GARLIQUE is the very highest
in allicin yield.
REJUVEX is uniquely positioned to support menopausal comfort and healthy bones
for women in the pre and post-menopausal age group. REJUVEX is a unique natural
formula containing a combination of magnesium, vitamins, anti-oxidants and other
important nutrients, which help meet the changing nutritional needs of women.
PROPALMEX is a leading branded product in the $43 million saw palmetto herbal
category. Positioned to support prostate health in men over 40, PROPALMEX is
backed by consumer promotion and extensive radio advertising. A new and improved
PROPALMEX formula will ship in the first quarter of 2000. This
5
new product adds lycopene, a powerful anti-oxidant, to clinically tested
standardized saw palmetto, to provide an all natural, drug free approach to
maintaining a healthy prostate.
HARMONEX is a unique combination of two herbs: St. John's Wort for emotional
well-being and Siberian ginseng for physical well-being. HARMONEX competes in
the St. John's Wort category now selling at the rate of $130 million per year.
The Company competes in the $33 million dollar melatonin category with
MELATONEX. The brand is positioned to support a natural sleep cycle. The product
uses a unique time-release delivery system, releasing melatonin as the body
does, gradually, while you sleep.
REPOSE Stress Relief Formula blends kava and magnesium for relaxation with
revitalizing Siberian ginseng to help the body deal with stress effectively.
Vitamins B and C complete the formula by replenishing nutrients that are lost
due to stress.
ECHINEX is a standardized herbal complex of echinacea, ginger and Siberian
ginseng. This unique and effective combination is positioned to support a
healthy immune system.
TOILETRIES AND SKIN CARE PRODUCTS
ANTIPERSPIRANTS AND DEODORANTS
The Company competes in the $1.7 billion antiperspirant and deodorant
category with its BAN products which provide advanced protection from odor
and wetness. Originally introduced in 1955, BAN is the number one roll-on
brand in the U.S. The proven maximum strength protection of BAN is available
in five advanced forms -- Original Roll-On, Clear Roll-On, Solid Stick, Clear
Stick and Clear Soft Solid. The product line is supported with significant
national television and radio advertising and consumer promotions. Two
exciting new line extensions, BAN Ultra Dry Roll-on and BAN Ultra Dry Stick,
and new packaging were introduced in the 1999 fiscal year.
FACIAL CLEANSERS AND MASQUES
Within the skin care category, the Company competes in the $718 million facial
cleanser category with its PHISODERM brand and in the $30 million facial masque
sub-segment with MUDD Spa Treatment masque products.
PHISODERM is a line of facial cleansers developed by dermatologists which
retains an ethical, skin smart halo. The line includes a bar soap and several
formulas of liquid cleansers, including one for infants. In 1999 PHISODERM
added a 4-Way Daily Acne Cleanser to the line which has generated significant
incremental new business to the brand. Consumer support behind the brand has
been in the form of radio advertising for the base products and print
advertising in teen magazines for the acne product in addition to extensive
sampling of all formulas. In 2000 we anticipate further expanding the acne
portion of the business with unique new line extensions.
MUDD is a line of deep cleaning, clay-based products for the face. Target
consumers for MUDD are women between the ages of 18 and 49. MUDD Masque is
available in four formulas and is a strong market leader in the masque category.
In 1999 the masque products were repackaged in a new terra cotta design and
upsized from 4 oz. to 6 oz. tubes. Also in 1999 the Company introduced MUDD
Self-Heating Skin Cleanser which is a deep cleaning scrub product. MUDD
Self-Heating Skin Cleanser is unique because it generates heat upon contact with
water to open pores for maximum deep cleansing.
6
SEASONALS
The Company competes in three seasonal product categories: sun care, spray-on
hair lighteners and chlorine removal haircare. The Company competes in the
$325 million sun care category among products with a sun protection factor
(SPF) of greater than 15 with the BULLFROG Sunblock line. SUN-IN competes in
the $12 million spray-on hair lightener category, while ULTRASWIM Shampoo,
Conditioner, Soap and Shower Gel dominate the small chlorine removal category.
BULLFROG is a line of waterproof sunblocks for outdoor active consumers. The
Company will continue to support the brand with a comprehensive plan which
includes an active new product program, increased consumer advertising, strong
promotions and targeted sampling programs. In 1999 two new products were added
to the line: BULLFROG MAGIC BLOCK, a disappearing color sunblock, and BULLFROG
QUIK STICK, the highest sun protection stick with aloe and vitamin E. In 2000,
BULLFROG will add three new products to the line: BULLFROG QUIK GEL Sport Spray,
an active sport spray version of the most popular selling BULLFROG QUIK GEL
formula, BULLFROG AgeProof, a high SPF daily wear sunblock with Parsol 1789,
and BULLFROG Sparkle Block, a disappearing color sunblock with sparkles.
SUN-IN is a dominant spray-in lightener in the haircare market. In 1999 SUN-IN
introduced Super Streaks, a hair lightener in a gel form similar to a styling
gel. This item, which offers the SUN-IN user a hair lightener with added
control, has provided incremental volume to the base business. The brand is
supported through strong consumer promotions executed on shelf and a seasonal
radio campaign on teen radio stations.
ULTRASWIM is the gold standard of chlorine removing shampoos, conditioners,
and soaps. ULTRASWIM has a unique formula that performs chlorine removal
better than any comparable hair care or skin care product on the market. The
company supports this brand through targeted print advertising to
competitive, recreational and exercise swimmers and through event sponsorship
with targeted sampling programs.
INTERNATIONAL MARKET OVERVIEW
EUROPE
Chattem's European business is conducted through Chattem (U.K.) Limited, a
wholly-owned subsidiary located in Basingstoke, Hampshire, England. This unit
also services distributors in Thailand, Taiwan, Australia and the Middle East.
Manufacturing and packaging of the products is conducted principally in the U.K.
with a limited number of ingredients purchased from Chattem. Chattem (U.K.)
employs its own sales force in the United Kingdom while distributors are used to
market and sell its products on the Western European Continent. Due to the
difficulty and expense involved in the registration of OTC health care brands in
Europe, the unit markets exclusively the Company's toiletry and skin care
products. Chattem's products in Europe include SUN-IN, a range of MUDD face and
body products and ULTRASWIM. CORNSILK is sold under a licensing arrangement with
another company. SPRAY BLOND Spray-In Hair Lightener is only marketed on the
European continent.
CANADA
Chattem (Canada) Inc. is a wholly-owned subsidiary based in Mississauga, Ontario
which markets and distributes certain of Chattem's consumer products throughout
Canada. The manufacturing of the brands is principally done in the Company's
facilities in Chattanooga while some packaging takes place in Mississauga. The
division utilizes a national broker for its sales efforts. Brands marketed and
sold in Canada include BAN, GOLD BOND, PAMPRIN, FLEXALL, MUDD, SUN-IN,
ULTRASWIM, PHISODERM, ASPERCREME and DEXATRIM.
7
U.S. EXPORT
The U.S. Export division services various distributors primarily located in the
Caribbean and Central and South America. The Company sells BAN, ICY HOT, GOLD
BOND, PAMPRIN, MUDD, PHISODERM and DEXATRIM into these markets with the primary
focus being the development of its OTC health care products.
8
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following analysis of the financial condition and results of operations
should be read in conjunction with the audited consolidated financial statements
and related notes thereto included elsewhere in this Annual Report.
GENERAL
Fiscal 1999 was highlighted by the acquisition of certain products from Thompson
Medical Company, Inc. ("Thompson") and related refinancing of senior debt, the
issuance of $75,000,000 of 8.875% senior subordinated notes, the repurchase of
172,500 shares of the Company's common stock, the retirement of $15,106,000 face
amount of 12.75% senior subordinated notes and, in addition to scheduled
principal payments, prepayments of $10,400,000 on long-term bank debt.
On December 21, 1998, the Company acquired the DEXATRIM, SPORTSCREME,
ASPERCREME, CAPZASIN-P, CAPZASIN-HP and ARTHRITIS HOT brands from Thompson (the
"Thompson Medical brands") for $95,000,000. The purchase price consisted of
$90,000,000 cash and 125,500 shares of the Company's common stock. The cash
portion of the purchase price was financed by a senior credit facility. The
purchase price of $95,000,000 was allocated $3,493,000 to inventory and
$91,507,000 to trademarks.
9
The Company also announced on December 21, 1998, the filing of a shelf
registration with the Securities and Exchange Commission for $250,000,000 of
debt and equity securities. This shelf filing allows the Company to access the
capital markets on a more immediate basis to fund internal growth and
acquisitions and strengthen the balance sheet.
On May 7, 1999, the Company issued an additional $75,000,000 of its 8.875%
(priced to yield 8.8125%) senior subordinated notes under its indenture relating
to the issuance of its $200,000,000 of 8.875% notes on March 24, 1998. The
additional notes mature on April 1, 2008 and were issued under the Company's
$250,000,000 shelf registration statement filed on December 21, 1998 with the
Securities and Exchange Commission. The net proceeds from the issuance of the
additional notes were used to retire $41,500,000 of the then outstanding balance
of the Company's $115,000,000 term bank loan and the outstanding balance of
$25,500,000 under its revolving bank loan dated December 21, 1998.
Concurrent with the closing of the $75,000,000 note issue, the Company
amended its senior credit facility. The amended facility, provided by a
syndicate of banks, consists of a $70,000,000 term loan maturing in quarterly
installments ranging from $2,000,000 to $4,750,000 through June 30, 2003 and
a $50,000,000 revolving credit facility maturing on December 21, 2003. The
credit facility contains covenants, representations, warranties and other
agreements by the Company that are customary in loan agreements relating to
financing of this type.
10
During the year ended November 30, 1999, the Company, in addition to
scheduled principal payments, prepaid $10,400,000 of its long-term bank debt
and $15,106,000 of its 12.75% senior subordinated notes. In connection with
the repayment of those borrowings, the Company recorded an extraordinary loss
of $2,385,000, net of income taxes, or $.24 per share. The loss primarily
related to the write-off of debt issuance costs connected with outstanding
long-term debt retired before maturity and the premium paid on the retirement
of the 12.75% notes.
During fiscal 1999, the Company redeemed 172,500 shares of its common stock,
without par value, for $3,912,000.
The results of operations for fiscal year 1999 reflect a full year of
operations of BAN, which was acquired in the second quarter of 1998, and
approximately eleven months' operations of the Thompson Medical brands, which
were purchased in December 1998.
The Company will continue to seek increases in sales through a combination of
acquisitions and internal growth while maintaining high operating income levels.
As previously high growth brands mature, sales increases will become more
dependent on acquisitions and the development of successful line extensions of
existing products. During fiscal 1999, the Company introduced the following line
extensions/new products: BAN Ultra Dry Roll-On, BAN Ultra Dry Solid Stick, GOLD
BOND Triple Antibiotic Ointment, REPOSE Stress Relief Formula from SUNSOURCE,
11
BULLFROG MAGIC BLOCK, SUN-IN Super Streaks, FLEXALL QUIK GEL, MUDD
Self-Heating Skin Cleanser and PHISODERM 4-Way Daily Acne Cleanser. Also, new
packaging for BAN was introduced in the second quarter of fiscal 1999. Line
extensions, product introductions and acquisitions require a significant
amount of introductory advertising and promotional support. For a period of
time these products do not generate a commensurate amount of sales and/or
earnings. As a result, the Company may experience a short-term impact on its
profitability. Strategically, the Company continually evaluates its products
as part of its growth strategy and, in instances where the Company's
objectives are not realized, will dispose of these brands and redeploy the
assets to acquire other brands or reduce indebtedness.
12
RESULTS OF OPERATIONS
The following table sets forth, for income before extraordinary loss and for
the periods indicated, certain items from the Company's Consolidated
Statements of Income expressed as a percentage of net sales. The fiscal 1997
results included a reclassification as described in Note 2 of the Company's
Notes to the Consolidated Financial Statements.
YEAR ENDED NOVEMBER 30
------------------------------------------
1999 1998 1997
---------- ---------- ----------
NET SALES .................................. 100.0% 100.0% 100.0%
----- ----- -----
COST AND EXPENSES:
Cost of sales ........................... 25.4 27.7 27.4
Advertising and promotion ............... 39.5 39.3 39.2
Selling, general and
administrative ........................ 10.9 12.4 15.6
----- ----- -----
Total costs and expenses .......... 75.8 79.4 82.2
----- ----- -----
INCOME FROM OPERATIONS ..................... 24.2 20.6 17.8
----- ----- -----
OTHER INCOME (EXPENSE):
Interest expense ........................ (12.3) (12.1) (11.4)
Investment and other income ............. .2 .4 1.2
Gain on product divestitures ............ -- 4.3 --
----- ----- -----
Total other income (expense) ..... (12.1) (7.4) (10.2)
----- ----- -----
INCOME BEFORE INCOME TAXES ................. 12.1 13.2 7.6
PROVISION FOR INCOME TAXES ................. 4.5 4.9 2.7
----- ----- -----
INCOME BEFORE EXTRAORDINARY
LOSS ..................................... 7.6% 8.3% 4.9%
===== ===== =====
FISCAL 1999 COMPARED TO FISCAL 1998
Net sales for the year ended November 30, 1999 increased $78,078,000, or 35.5%,
to $298,142,000 from $220,064,000 for the previous fiscal year. The increase
consisted of a $76,821,000, or 38.4%, increase in domestic consumer products
13
sales from $199,811,000 in 1998 to $276,632,000 in 1999 and an increase of
$1,257,000, or 6.2%, in international sales to $21,510,000 from $20,253,000.
For domestic consumer products, sales of BAN, the Thompson Medical brands and
GOLD BOND accounted for the majority of the sales increase in 1999. Sales
increases were also realized for the FLEXALL, HERPECIN-L, MUDD and PHISODERM
brands. Sales declines were recognized for the PREMSYN PMS, ULTRASWIM, NORWICH
Aspirin and SUNSOURCE product lines. Sales were also affected by the disposition
of the CORNSILK brand in May 1998. The remaining domestic brands were basically
flat or had modest declines over the prior fiscal year. All sales variances were
largely the result of changes in the volume of unit sales of the particular
brand.
The increase in the sales of the GOLD BOND brand was primarily due to the
introduction of the line extensions of medicated lotion in mid-1998 and
antibiotic ointment in early 1999. HERPECIN-L sales benefited from more
effective marketing support, while FLEXALL, MUDD and PHISODERM realized
incremental sales from the introductions of QUIK GEL, Self-Heating Skin
Cleanser and 4-Way Daily Acne Cleanser, respectively, in 1999.
The sales declines for the PREMSYN PMS, ULTRASWIM and NORWICH Aspirin product
lines were largely the result of decreased marketing support and the maturation
of these brands. The decrease in sales of the SUNSOURCE products was
attributable to a general decline in sales of the dietary supplements market
14
category and increased competition. The modest sales declines experienced by
certain of the other domestic products were primarily due to increased
competition in their respective categories, the maturation of these brands
and, in certain cases, reduced marketing support.
In fiscal 1999 sales of the international consumer products segment increased
$1,377,000, or 25.9%, for the Canadian operation, but declined $335,000, or
3.0%, for the United Kingdom business. BAN, the Thompson Medical brands and the
GOLD BOND product line accounted for the net sales increase in Canada, while
sales decreases were recognized for all of the product lines marketed by the
United Kingdom operation, except for BAN sales to the Far East. The limited
number of product lines offered and increased competition contributed to the
decline in the United Kingdom business. U.S. export sales increased $215,000, or
5.6%, to $4,054,000 in 1999 from $3,839,000 in 1998, with most of the increase
associated with BAN, the Thompson Medical brands and GOLD BOND. All sales
variances were largely the result of changes in the volume of unit sales of the
particular brand.
Cost of goods sold as a percentage of net sales in 1999 was 25.4% compared to
27.7% in 1998. This improvement was principally due to increased sales of higher
gross margin brands and more efficient purchasing and manufacturing operations.
Advertising and promotion expenses increased $31,243,000, or 36.1%, to
$117,835,000 in 1999 from $86,592,000 in 1998 and were 39.5% of net sales
compared to 39.3% in 1998. This increase was largely associated with advertising
15
and promotional expense incurred in connection with BAN, the Thompson Medical
brands, GOLD BOND and PHISODERM. Increases in advertising and promotion in
1999 were also recorded for FLEXALL, SUN-IN, MUDD and REPOSE of the SUNSOURCE
product line. Declines in spending were recorded for the PAMPRIN, ICY HOT,
PREMSYN PMS, HERPECIN-L and SUNSOURCE (except for REPOSE) product lines.
Selling, general and administrative expenses increased $5,130,000, or 18.7%, to
$32,494,000 in 1999 from $27,364,000 in 1998 but decreased as a percentage of
net sales to 10.9% in 1999 from 12.4% in 1998. This dollar increase was largely
associated with increases in direct selling costs, freight and field sales
expenses as a result of increased sales from acquired brands and associated
increases in corporate administrative and service departmental expenses. The
decline in 1999 from 1998 in the percentage of selling, general and
administrative expenses to net sales reflected the increase in net sales without
a corresponding increase in overhead costs.
Interest expense increased $9,896,000, or 37.1%, to $36,572,000 in 1999 from
$26,676,000 in 1998 primarily as a result of increased indebtedness associated
with the acquisitions of BAN and the Thompson Medical brands. Until the
Company's indebtedness is reduced substantially, interest expense will continue
to represent a significant percentage of the Company's net sales.
16
Investment and other income decreased $302,000, or 34.3% to $579,000 in 1999
from $881,000 in 1998. The decrease was due primarily to the Company's sale of
its remaining investment in Elcat, Inc.
A gain of $9,548,000 on the sale of the CORNSILK brand was recognized in 1998.
Income before extraordinary loss increased $4,413,000, or 24.3%, to $22,541,000
in 1999 from $18,128,000 in 1998, which includes the gain of $6,302,000, net of
taxes, from the sale of CORNSILK. This increase resulted primarily from
increased sales, offset in part by increases in sales related costs and interest
expense.
Cash earnings (net income before extraordinary loss on early extinguishment
of debt plus non-cash amortization) is one of the key standards used by the
Company to measure operating performance. Cash earnings is used to supplement
operating income as an indicator of operating performance and not as an
alternative to measures defined and required by generally accepted accounting
principles.
Cash earnings (net income before extraordinary loss on early extinguishment
of debt plus non-cash amortization) for fiscal 1999 were $29,507,000, or $2.94
per share, as compared to $16,550,000, or $1.70 per share, for fiscal 1998, a
78.3% increase in cash earnings. The Company's earnings before interest,
taxes, depreciation and amortization (EBITDA) for fiscal 1999 was $85,383,000
as compared to $53,889,000 for fiscal 1998, a 58.4% increase. The EBITDA
margin increased from 24.5% of net sales in 1998 to 28.6% in 1999.
17
FISCAL 1998 COMPARED TO FISCAL 1997
Net sales for the year ended November 30, 1998 increased $76,829,000, or 53.6%,
to $220,064,000 from $143,235,000 for the previous fiscal year. The increase
consisted of a $71,787,000, or 56.1%, increase in domestic consumer products
sales from $128,024,000 in 1997 to $199,811,000 in 1998 and an increase of
$5,042,000, or 33.1%, in international sales to $20,253,000 from $15,211,000.
For domestic consumer products, sales of the BAN, SUNSOURCE and GOLD BOND
products accounted for the majority of the sales increase in 1998. Sales
increases were also realized for the PAMPRIN, SUN-IN and BULLFROG brands.
Sales declines were recognized for FLEXALL, ICY HOT, NORWICH Aspirin, MUDD
and PHISODERM. The remaining domestic brands were basically flat or had
modest declines over the prior fiscal year. All sales variances were largely
the result of changes in the volume of unit sales of the particular brand.
The increase in sales of the GOLD BOND brand was due primarily to the
introduction of the lotion line extension in 1998 and also the growth of the
existing business. The sales increases for the PAMPRIN and BULLFROG product
lines were principally the result of increased marketing expenditures. Also for
BULLFROG, the introduction of two new products and a new major customer, both
18
occurring in 1998, had a favorable impact on that product line's 1998 sales.
BAN was acquired in March 1998 and the SUNSOURCE product line was purchased
in June 1997.
The sales declines for the FLEXALL, ICY HOT, MUDD and PHISODERM brands were
principally the result of decreased advertising and promotional support. Sales
were also affected by disposition of CORNSILK in May 1998. The modest sales
declines experienced by certain of the other domestic products were essentially
due to increased competition in their respective categories, the maturation of
these brands and, in certain cases, reduced marketing expenditures.
In fiscal 1998, sales for the international consumer products segment increased
$447,000, or 9.2%, for the Canadian operation and $1,808,000, or 19.5%, for the
United Kingdom business. BAN accounted for the majority of the net sales
increase in Canada, while increases were also realized for the PAMPRIN, SUN-IN
and GOLD BOND brands. Sales increases were realized for all of the product lines
marketed by the United Kingdom operation. U.S. export sales increased
$2,787,000, or 264.8%, to $3,839,000 in 1998 from $1,052,000 in 1997, with
essentially all of the increase being associated with BAN. All sales variances
were largely the result of changes in the volume of unit sales of the particular
brand.
Cost of goods sold as a percentage of net sales in 1998 was essentially
unchanged at 27.7% versus 27.4% for 1997. Cost of sales was affected by the full
19
year favorable impact of the SUNSOURCE line which was slightly more than
offset by the unfavorable impact of the BAN acquisition.
Advertising and promotion expenses increased $30,416,000, or 54.1%, to
$86,592,000 in 1998 from $56,176,000 in 1997 and were 39.3% of net sales
compared to 39.2% in 1997. This increase was principally associated with
advertising and promotional expenses incurred in connection with BAN, acquired
in March 1998, a full year of the SUNSOURCE brands and GOLD BOND. Increases in
advertising and promotion in 1998 were also recorded for the PAMPRIN and
BULLFROG brands.
Selling, general and administrative expenses increased $5,061,000, or 22.7%, to
$27,364,000 in 1998 from $22,303,000 in 1997, but decreased as a percentage of
net sales to 12.4% in 1998 as compared to 15.6% in 1997. This dollar increase
was largely associated with increases in direct selling costs, freight, bad
debts and field sales expenses as a result of increased sales from acquired
brands and associated increases in administrative, financial and legal services.
Interest expense increased $10,357,000, or 63.5%, to $26,676,000 in 1998 from
$16,319,000 in 1997 primarily as a result of increased indebtedness associated
with the BAN product acquisition in March 1998 and the SUNSOURCE brands'
purchase in mid-1997.
20
Investment and other income decreased $798,000, or 47.5%, to $881,000 in 1998
from $1,679,000 in 1997. The decrease was due primarily to the Company's sale of
a portion of its investment in Elcat, Inc.
A gain of $9,548,000 on the sale of the CORNSILK brand was recognized in 1998.
Income before extraordinary loss increased $11,112,000, or 158.4%, to
$18,128,000 in 1998 from $7,016,000 in 1997. This increase resulted primarily
from increased sales and the gain on the sale of the CORNSILK brand.
21
LIQUIDITY AND CAPITAL RESOURCES
The Company has historically financed its operations and acquisitions with a
combination of internally generated funds and borrowings. The Company's
principal uses of cash are operating expenses, servicing long-term debt,
acquisitions, working capital and capital expenditures.
Cash provided by operating activities was $26,922,000 and $20,790,000 for 1999
and 1998, respectively. The increase in cash flows from operations from 1998 to
1999 was primarily the result of increases in net income, depreciation and
amortization, accounts payable and accrued liabilities. The operating activities
were favorably impacted by the acquisition of the SUNSOURCE product line in
1997, BAN in 1998 and the Thompson Medical brands in 1999.
Investing activities used cash of $100,504,000 and $161,595,000 in 1999 and
1998, respectively. The use of cash in 1999 reflected the expenditures required
for the purchase of the Thompson Medical brands, while the 1998 amount
represented the purchase of BAN in that year. In 1999, capital expenditures
totaled $9,830,000 compared to $9,050,000 in 1998. The increase was due
primarily to cost of the replacement of the Company's information technology
systems and the cost of the extensive renovation of the manufacturing and
warehouse facility purchased in fiscal 1998. Capital expenditures are expected
to be approximately $7,000,000 in fiscal 2000.
22
Financing activities provided cash of $73,770,000 in 1999 and $138,090,000 in
1998. In December 1998 the Company financed the acquisition of the Thompson
Medical brands with the proceeds of a $90,000,000 bank credit agreement and
125,500 shares of common stock valued at approximately $39.84 per share. In 1998
the Company financed the acquisition of BAN and repaid all revolving bank
indebtedness with the proceeds from its issuance of $200,000,000 of 8.875%
Senior Subordinated Notes due 2008.
The potential future SUNSOURCE deferred payments were settled in their entirety
by the Company with a $1,650,000 cash payment and the issuance of 2,582 shares
of its common stock on November 30, 1999 to the former owners of SUNSOURCE.
Until June 30, 2003, the Company is obligated to pay an annual royalty on
HERPECIN-L for the greater of $214,000, or 5% of annual net sales.
23
The following table presents certain working capital data at November 30, 1999
and 1998 or for the respective years then ended:
ITEM 1999 1998
-------------------------------- ---------- ----------
Working capital (current assets less
current liabilities) ............. $ 26,413,000 $ 684,000
Current ratio (current assets divided
by current liabilities) .......... 1.40 1.01
Quick ratio (cash and cash equivalents
and receivables divided by current
liabilities) ..................... .86 .63
Average accounts receivable turnover . 6.51 6.81
Average inventory turnover ........... 3.19 3.57
Working capital as a percentage of
total assets .................... 5.37% 0.19%
The increase in the current and quick ratios at November 30, 1999 as compared to
November 30, 1998 was primarily due to increases in accounts receivables and
inventories offset in part by increases in accounts payable, payable to bank and
accrued liabilities. These increases were due in part to the acquisition of the
Thompson Medical brands in December 1998.
24
Total debt outstanding at November 30, 1999 was $369,950,000 compared to
$291,357,000 at November 30, 1998. The net increase of $78,593,000 in 1999
reflected the financing of the acquisition of the Thompson Medical brands offset
by debt repayments. The Company had $5,000,000 of outstanding borrowings and
$45,000,000 available to borrow on its $50,000,000 working capital line of
credit as of November 30, 1999.
Management of the Company believes that cash generated by operations along
with available funds under its credit facility will be sufficient to fund the
Company's current commitments and proposed operations. As of November 30,
1999, the remaining amount authorized by the Company's board of directors
under the Stock Buyback plan was $6,088,000. Also on December 21, 1998, the
Company filed with the Securities and Exchange Commission a shelf
registration for $250,000,000 of debt and equity securities, of which
$75,000,000 was utilized in the sale of the 8.875% Notes in May 1999.
25
YEAR 2000
The Company has successfully completed the replacement of its previous
information technology (IT) systems with those that are year 2000 compliant.
The cost of the new IT systems to date is approximately $3,230,000, which has
been capitalized.
To date the Company has experienced no major problems with its implementation,
nor has it encountered any unusual situations with its principal customers and
suppliers in connection with their year 2000 IT systems' compliance.
However, if unanticipated problems arise in the future with regard to year 2000
compliance with the Company's new IT systems or those of its principal
customers and suppliers, the Company's business could be adversely affected.
26
FOREIGN OPERATIONS
The Company's primary foreign operations are conducted through its Canadian and
United Kingdom subsidiaries. The functional currencies of these subsidiaries are
Canadian dollars and British pounds, respectively. Fluctuations in exchange
rates can impact operating results, including total revenues and expenses, when
translations of the subsidiary financial statements are made in accordance with
SFAS No. 52, "Foreign Currency Translation." For the years ended November 30,
1999 and 1998, these subsidiaries accounted for 5.9% and 7.5% of total revenues,
respectively, and 2.0% and 2.4% of total assets, respectively. It has not been
the Company's practice to hedge its assets and liabilities in Canada and the
United Kingdom or its intercompany transactions due to the inherent risks
associated with foreign currency hedging transactions and the timing of payment
between the Company and its two foreign subsidiaries. Historically, gains or
losses from foreign currency transactions have not had a material impact on the
Company's operating results. Losses of $26,000 and $74,000 for the years ended
November 30, 1999 and 1998, respectively, resulted from foreign currency
transactions. See "Foreign Currency Translation" in Note 2 of Notes to
Consolidated Financial Statements.
27
RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS
In April 1998, the AICPA issued Statement of Position (SOP) 98-5 "Reporting on
the Costs of Start-Up Activities". SOP 98-5 requires costs of start-up
activities and organization costs to be expensed as incurred. This SOP is
effective for financial statements for fiscal years beginning after December 15,
1998. The Company will record the initial application of this SOP in December
1999 as the cumulative effect of a change in accounting principle of
approximately $875,000.
In June 1998, the Financial Accounting Standards Board issued SFAS No. 133,
"Accounting for Derivative Instruments and Hedging Activities." SFAS No. 133
established accounting and reporting standards requiring that every derivative
instrument (including certain derivative instruments embedded in other
contracts) be recorded in the balance sheet as either an asset or liability
measured at its fair value. SFAS No. 133 requires that changes in the
derivative's fair value be recognized currently in earnings unless specific
hedge accounting criteria are met. Special accounting for qualifying hedges
allow a derivative's gains and losses to offset related results on the hedged
item in the income statement, and requires that a company must formally
document, designate and assess the effectiveness of transactions that receive
hedge accounting. SFAS No. 137 delayed the effective date of SFAS No. 133 until
fiscal years beginning after June 15, 2000. A company may also implement SFAS
No. 133 as of the beginning of any fiscal quarter after issuance. SFAS No. 133
cannot be applied retroactively. SFAS No. 133 must be applied to (a) derivative
instruments and (b) certain derivative instruments embedded in hybrid contracts
28
that were issued, acquired or substantively modified after December 31, 1997
(and, at the Company's election, before January 1, 1999). SFAS No. 133 could
increase volatility in earnings and other comprehensive income, however,
based on the Company's current and anticipated level of derivative
instruments and hedging activities, the Company does not believe the impact
would be material.
SEASONALITY
During recent fiscal years, the Company's first quarter's net sales and gross
profit have trailed the other fiscal quarters on average from 25% to 35% because
of slower sales of domestic and international consumer products and the relative
absence of promotional campaigns during this quarter. As a result of the
Company's acquisitions of BAN and the Thompson Medical brands and the new line
extensions, seasonality should not be as pronounced as in years past; however,
net sales and gross profit during the first fiscal quarter will continue to
trail the other fiscal quarters.
FORWARD LOOKING STATEMENTS
The Company may from time to time make written and oral forward looking
statements. Written forward looking statements may appear in documents filed
with the Securities and Exchange Commission, in press releases and in reports to
shareholders. The Private Securities Litigation Reform Act of 1995 contains a
safe harbor for forward looking statements. The Company relies on this safe
29
harbor in making such disclosures. The forward looking statements are based
on managements's current beliefs and assumptions about expectations,
estimates, strategies and projections for the Company. These statements are
not guarantees of future performance and involve risks, uncertainties and
assumptions that are difficult to predict. Therefore, actual outcomes and
results may differ materially from what is expressed or forecasted in such
forward looking statements. The Company undertakes no obligation to update
publicly any forward looking statements whether as a result of new
information, future events or otherwise. The risks, uncertainties and
assumptions regarding forward looking statements include, but are not limited
to, product demand and market acceptance risks; product development risks,
such as delays or difficulties in developing, producing and marketing new
products or line extensions; the impact of competitive products, pricing and
advertising; constraints resulting from financial condition of the Company,
including the degree to which the Company is leveraged, debt service
requirements and restrictions under bank loan agreements and indentures;
government regulations; risks of loss of material customers; public
perception regarding the Company's products; dependence on third party
manufacturers; environmental matters; product liability and insurance; year
2000; and other risks described in the Company's Securities and Exchange
Commission filings.
30
SELECTED FINANCIAL DATA
(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)
YEAR ENDED NOVEMBER 30,
------------------------------------------------------------------------------------
1999 1998 1997 1996 1995
---- ---- ---- ---- ----
INCOME STATEMENT DATA
NET SALES .............. $ 298,142 $ 220,064 $ 143,235 $ 118,903 $ 100,598
OPERATING COSTS AND
EXPENSES ............. 225,941 174,845 117,732 102,214 86,130
--------- --------- --------- --------- ---------
INCOME FROM OPERATIONS . 72,201 45,219 25,503 16,689 14,468
OTHER EXPENSE, NET ..... (35,993) (16,247) (14,640) (11,069) (10,858)
--------- --------- --------- --------- ---------
INCOME FROM CONTINUING
OPERATIONS BEFORE
INCOME TAXES AND
EXTRAORDINARY LOSS ... 36,208 28,972 10,863 5,620 3,610
PROVISION FOR INCOME
TAXES ................ 13,667 10,844 3,847 1,816 1,285
--------- --------- --------- --------- ---------
INCOME FROM CONTINUING
OPERATIONS BEFORE
EXTRAORDINARY LOSS ... $ 22,541 $ 18,128 $ 7,016 $ 3,804 $ 2,325
========= ========= ========= ========= =========
PER SHARE DATA
INCOME PER DILUTED SHARE
FROM CONTINUING
OPERATIONS BEFORE
EXTRAORDINARY LOSS ... $ 2.25 $ 1.86 $ .77 $ .47 $ .32
========= ========= ========= ========= =========
BALANCE SHEET DATA
(At End of Period)
TOTAL ASSETS.......... $ 491,624 $ 369,012 $ 178,744 $ 152,183 $ 83,410
========= ========= ========= ========= =========
LONG-TERM DEBT, less
current maturities . $ 358,950 $ 273,913 $ 133,475 $ 127,438 $ 78,089
========= ========= ========= ========= =========
31
MARKET PRICES
The Company's common shares trade over-the-counter on the National Market System
under the NASDAQ symbol CHTT. A quarterly summary of the high and low market
prices per common share as reported by NASDAQ is shown below:
1999 1998
--------------------- -------------------
QUARTER ENDED: HIGH LOW HIGH LOW
---- --- ---- ---
February ..... 50 1/4 24 5/8 23 5/8 12 7/8
May .......... 41 11/16 29 3/4 30 1/2 19 3/8
August ....... 38 3/8 24 37 7/8 18 5/8
November ..... 28 1/8 17 5/8 43 1/8 18 5/8
Based upon transfer agent records, the Company's common shares were held by
approximately 2,500 shareholders as of February 24, 2000.
32
CONSOLIDATED BALANCE SHEETS
NOVEMBER 30, 1999 AND 1998
(IN THOUSANDS)
1999 1998
---- ----
ASSETS
CURRENT ASSETS:
Cash and cash equivalents ............................................... $ 2,308 $ 2,076
Accounts receivable, less allowance for doubtful accounts
of $900 in 1999 and $775 in 1998 ....................................... 55,032 36,581
Deferred income taxes ................................................... 6,951 3,049
Inventories ............................................................. 27,818 19,606
Prepaid expenses and other current assets ............................... 929 784
-------- --------
Total current assets ................................................. 93,038 62,096
-------- --------
PROPERTY, PLANT AND EQUIPMENT, NET ....................................... 25,752 18,146
-------- --------
OTHER NONCURRENT ASSETS:
Investment in Elcat, Inc. ............................................... -- 3,102
Patents, trademarks and other purchased
product rights, net .................................................... 356,295 272,226
Debt issuance costs, net ................................................ 11,469 10,091
Other ................................................................... 5,070 3,351
-------- --------
Total other noncurrent assets ........................................ 372,834 288,770
-------- --------
TOTAL ASSETS ........................................................ $491,624 $369,012
======== ========
THE ACCOMPANYING NOTES ARE AN INTEGRAL PART OF THESE CONSOLIDATED
FINANCIAL STATEMENTS.
33
CONSOLIDATED BALANCE SHEETS
NOVEMBER 30, 1999 AND 1998
(IN THOUSANDS)
1999 1998
---- ----
LIABILITIES AND SHAREHOLDERS' EQUITY
CURRENT LIABILITIES:
Current maturities of long-term debt ...................... $ 11,000 $ 17,444
Accounts payable .......................................... 18,573 12,733
Payable to bank ........................................... 4,905 1,026
Accrued liabilities ....................................... 32,147 30,209
--------- ---------
Total current liabilities ............................... 66,625 61,412
--------- ---------
LONG-TERM DEBT, less current maturities .................... 358,950 273,913
--------- ---------
DEFERRED INCOME TAXES ...................................... 15,326 6,826
--------- ---------
OTHER NONCURRENT LIABILITIES ............................... 2,022 2,110
--------- ---------
COMMITMENTS AND CONTINGENCIES (Notes 5, 10 and 12)
SHAREHOLDERS' EQUITY:
Preferred shares, without par value, authorized 1,000,
none issued .............................................. -- --
Common shares, without par value, authorized 50,000 in 1999
and 20,000 in 1998, issued 9,707 in 1999 and 9,574
in 1998 .................................................. 2,021 1,994
Paid-in surplus ........................................... 72,850 69,068
Accumulated deficit ....................................... (24,804) (44,960)
--------- ---------
50,067 26,102
Cumulative other comprehensive income--
Foreign currency translation adjustment ................. (1,366) (1,351)
--------- ---------
Total shareholders' equity .............................. 48,701 24,751
--------- ---------
TOTAL LIABILITIES AND SHAREHOLDERS'
EQUITY ............................................... $ 491,624 $ 369,012
========= =========
THE ACCOMPANYING NOTES ARE AN INTEGRAL PART OF THESE CONSOLIDATED
FINANCIAL STATEMENTS.
34
CONSOLIDATED STATEMENTS OF INCOME
FOR THE YEARS ENDED NOVEMBER 30, 1999, 1998 AND 1997
(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)
1999 1998 1997
---- ---- ----
NET SALES ........................................ $ 298,142 $ 220,064 $ 143,235
--------- --------- ---------
COSTS AND EXPENSES:
Cost of sales .................................. 75,612 60,889 39,253
Advertising and promotion ...................... 117,835 86,592 56,176
Selling, general and administrative ............ 32,494 27,364 22,303
--------- --------- ---------
Total costs and expenses ..................... 225,941 174,845 117,732
--------- --------- ---------
INCOME FROM OPERATIONS ........................... 72,201 45,219 25,503
--------- --------- ---------
OTHER INCOME (EXPENSE):
Interest expense ............................... (36,572) (26,676) (16,319)
Investment and other income, net ............... 579 881 1,679
Gain on product divestiture .................... -- 9,548 --
--------- --------- ---------
Total other income (expense) ................. (35,993) (16,247) (14,640)
--------- --------- ---------
INCOME BEFORE INCOME TAXES AND
EXTRAORDINARY LOSS ........................... 36,208 28,972 10,863
PROVISION FOR INCOME TAXES ....................... 13,667 10,844 3,847
--------- --------- ---------
INCOME BEFORE EXTRAORDINARY LOSS ................. 22,541 18,128 7,016
EXTRAORDINARY LOSS ON EARLY
EXTINGUISHMENT OF DEBT, NET OF INCOME
TAXES (Note 5) ............................... (2,385) (2,859) (1,131)
--------- --------- ---------
NET INCOME ....................................... $ 20,156 $ 15,269 $ 5,885
========= ========= =========
COMMON SHARES:
Weighted average number outstanding (basic) .. 9,747 9,374 8,793
========= ========= =========
Weighted average and dilutive potential number
outstanding ................................. 10,024 9,735 9,123
========= ========= =========
NET INCOME (LOSS) PER COMMON SHARE:
Basic:
Income before extraordinary loss ............ $ 2.31 $ 1.93 $ .80
Extraordinary loss .......................... (.24) (.30) (.13)
--------- --------- ---------
Total basic ............................ $ 2.07 $ 1.63 $ .67
========= ========= =========
Diluted:
Income before extraordinary loss ............ $ 2.25 $ 1.86 $ .77
Extraordinary loss .......................... (.24) (.29) (.12)
--------- --------- ---------
Total .................................. $ 2.01 $ 1.57 $ .65
========= ========= =========
THE ACCOMPANYING NOTES ARE AN INTEGRAL PART OF THESE CONSOLIDATED
FINANCIAL STATEMENTS.
35
CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY
FOR THE YEARS ENDED NOVEMBER 30, 1999, 1998 AND 1997
(IN THOUSANDS, EXCEPT SHARE DATA)
Minimum Foreign
Pension Currency
Common Paid-in Accumulated Liability Translation
Shares Surplus Deficit Adjustment Adjustment Total
------ ------- ------- ---------- ---------- -----
Balance, November 30, 1996 ............ $ 1,843 $ 58,561 $(66,114) $(112) $(1,358) $ (7,180)
Net income .......................... -- -- 5,885 -- -- 5,885
Stock options exercised ............. 25 962 -- -- -- 987
Stock warrants exercised ............ 15 464 -- -- -- 479
Issuance of 300,000 common shares
in connection with product
acquisitions ...................... 62 3,988 -- -- -- 4,050
Foreign currency translation
adjustment ....................... -- -- -- -- 37 37
Minimum pension liability
adjustment ....................... -- -- -- 112 -- 112
------- -------- -------- ----- ------- --------
Balance, November 30, 1997 ............ 1,945 63,975 (60,229) -- (1,321) 4,370
Net income .......................... -- -- 15,269 -- -- 15,269
Stock options exercised ............. 28 3,699 -- -- -- 3,727
Stock warrants exercised ............ 21 1,394 -- -- -- 1,415
Foreign currency translation
adjustment ........................ -- -- -- -- (30) (30)
------- -------- -------- ----- ------- --------
Balance, November 30, 1998 ............ 1,994 69,068 (44,960) -- (1,351) 24,751
Net income .......................... -- -- 20,156 -- -- 20,156
Stock options exercised ............. 10 1,775 -- -- -- 1,785
Stock warrants exercised ............ 26 860 -- -- -- 886
Stock repurchases ................... (36) (3,876) -- -- -- (3,912)
Issuance of 128,082 common shares
in connection with product
acquisitions ...................... 27 5,023 -- -- -- 5,050
Foreign currency translation
adjustment ........................ -- -- -- -- (15) (15)
------- -------- -------- ----- ------- --------
Balance, November 30, 1999 ............ $ 2,021 $ 72,850 $(24,804) $ -- $(1,366) $ 48,701
======= ======== ======== ======= ======= ========
THE ACCOMPANYING NOTES ARE AN INTEGRAL PART OF THESE CONSOLIDATED
FINANCIAL STATEMENTS.
36
CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE YEARS ENDED NOVEMBER 30, 1999, 1998 AND 1997
(IN THOUSANDS)
1999 1998 1997
--------- --------- --------
OPERATING ACTIVITIES:
Net income ........................................... $ 20,156 $ 15,269 $ 5,885
Adjustments to reconcile net income to net cash
provided by operating activities:
Depreciation and amortization ...................... 15,064 9,827 6,381
Deferred income tax provision ...................... 4,598 2,351 974
Gain on product divestiture ........................ -- (9,548) --
Extraordinary loss on early extinguishment of
debt, net ......................................... 2,385 2,859 1,131
Dividend receivable from Elcat, Inc. ............... (279) (462) (656)
Other, net ......................................... -- (28) (106)
Changes in operating assets and liabilities, net
of acquisitions:
Accounts receivable ........................... (17,428) (12,054) (5,140)
Inventories ................................... (4,683) 1,836 (2,401)
Prepaid expenses and other current assets ..... (159) (102) 3,034
Accounts payable and accrued liabilities ...... 7,268 10,842 1,014
-------- -------- -------
Net cash provided by operating activities .... 26,922 20,790 10,116
-------- -------- -------
INVESTING ACTIVITIES:
Purchases of property, plant and equipment ........... (9,830) (9,050) (2,758)
Proceeds from sale of investments .................... 3,381 4,000 --
Proceeds from product divestitures ................... -- 11,965 --
Proceeds from notes and sales of assets .............. 272 1,085 75
Purchases of patents, trademarks and other product
rights .............................................. (91,127) (168,402) (29,293)
Increase in other assets ............................. (3,200) (1,193) (746)
--------- --------- --------
Net cash used in investing activities ........ (100,504) (161,595) (32,722)
--------- --------- --------
FINANCING ACTIVITIES:
Repayment of long-term debt ........................ (165,481) (145,028) (76,636)
Proceeds from long-term debt ....................... 242,281 291,365 87,500
Change in payable to bank .......................... 3,879 (1,592) 908
Repurchase of common shares ........................ (3,912) -- --
Exercise of stock options and warrants ............. 2,104 3,316 1,274
Debt issuance costs ................................ (5,101) (9,971) (1,612)
--------- --------- --------
Net cash provided by financing activities .... 73,770 138,090 11,434
--------- --------- --------
EFFECT OF EXCHANGE RATE CHANGES ON CASH
AND CASH EQUIVALENTS .............................. 44 (67) (10)
--------- --------- --------
CASH AND CASH EQUIVALENTS:
Increase (decrease) for the year ................... 232 (2,782) (11,182)
At beginning of year ............................... 2,076 4,858 16,040
--------- --------- --------
At end of year ..................................... $ 2,308 $ 2,076 $ 4,858
========= ========= ========
SCHEDULE OF NON-CASH INVESTING AND FINANCING
ACTIVITIES:
Issuance of 125,500 shares of common stock at $39.84
per share to fund portion of Thompson Medical
brands' acquisition .............................. $ 5,000 $ -- $ --
Issuance of 2,582 shares of common stock at $19.365
per share as part of agreement to settle future
contingency payments to the former owners of
SUNSOURCE ........................................ $ 50 $ -- $ --
Issuance of 300,000 shares of common stock at $13.50
per share to fund portion of SUNSOURCE
acquisition ...................................... $ -- $ -- $ 4,050
Additions to trademarks and other product rights by
assumption of certain liabilities ................ $ 1,525 $ 8,000 $ --
THE ACCOMPANYING NOTES ARE AN INTEGRAL PART OF THESE CONSOLIDATED
FINANCIAL STATEMENTS.
37
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
NOTE: ALL MONETARY AMOUNTS ARE EXPRESSED IN THOUSANDS OF DOLLARS UNLESS
CONTRARILY EVIDENT.
(1) NATURE OF OPERATIONS
Chattem, Inc. and its wholly-owned subsidiaries (the Company) market
and manufacture branded consumer products in two primary segments,
over-the-counter (OTC) health care products and toiletries and skin care
products. The products are sold primarily through mass merchandisers,
independent and chain drug stores, drug wholesalers, and food stores in the
United States and in various markets in approximately 50 countries throughout
the world.
(2) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
BASIS OF CONSOLIDATION
The accompanying consolidated financial statements include the accounts of
Chattem, Inc. and its wholly-owned subsidiaries. All significant intercompany
transactions and balances have been eliminated.
CASH AND CASH EQUIVALENTS
The Company considers all short-term deposits and investments with original
maturities of three months or less to be cash equivalents.
INVENTORIES
Inventory costs include materials, labor and factory overhead. Inventories
in the United States are valued at the lower of last-in, first-out (LIFO) cost
or market, while international inventories are valued at the lower of first-in,
first-out (FIFO) cost or market.
PROPERTY, PLANT AND EQUIPMENT
Property, plant and equipment are recorded at cost. The Company capitalized
interest of $255, $0 and $0 in 1999, 1998 and 1997, respectively. Depreciation
is computed using the straight-line method over the estimated useful lives of 10
to 40 years for buildings and improvements and 3 to 12 years for machinery and
equipment. Expenditures for maintenance and repairs are charged to expense as
incurred. Depreciation expense for 1999, 1998 and 1997 was $1,936, $1,597 and
$1,502, respectively.
38
PATENTS, TRADEMARKS AND OTHER PURCHASED PRODUCT RIGHTS
The costs of acquired patents, trademarks and other purchased product
rights are capitalized and amortized over periods ranging from 5 to 40 years. At
November 30, 1999 the weighted average life of patents, trademarks and other
purchased product rights was 26.7 years. Total accumulated amortization of these
assets at November 30, 1999 and 1998 was $26,393 and $17,382, respectively.
Amortization expense for 1999, 1998 and 1997 was $9,874, $6,180 and $2,877,
respectively. Royalty expense related to other purchased product rights for
1999, 1998 and 1997 was $498, $523 and $522, respectively. Amortization and
royalty expense are included in advertising and promotion expense in the
accompanying consolidated statements of income.
The Company continually evaluates whether events and circumstances have
occurred that indicate the remaining useful life of long-lived assets might
warrant revision or that the remaining balance may not be recoverable. When
factors indicate that long-lived assets should be evaluated for possible
impairment, the Company uses an estimate of the future undiscounted net cash
flows of the related assets over the remaining lives of the assets in
measuring whether long-lived assets are recoverable.
DEBT ISSUANCE COSTS
The Company has incurred debt issuance costs in connection with its
long-term debt. These costs are capitalized and amortized over the term of the
debt. Amortization expense related to debt issuance costs was $1,556, $986 and
$490 in 1999, 1998 and 1997, respectively. Accumulated amortization of these
costs was $2,859 and $1,814 at November 30, 1999 and 1998, respectively.
PAYABLE TO BANK
Payable to bank includes checks outstanding in excess of certain cash
balances.
REVENUE RECOGNITION
Revenue is recognized when the Company's products are shipped to its
customers.
It is the Company's policy across all classes of customers that all sales
are final. As is common in the consumer products industry, product is returned
by the customer due to a number of reasons. Examples include product damaged in
transit, discontinuance of a particular size or form of product, shipping error,
etc. The Company maintains and evaluates an allowance for returns and will
record a return upon receipt of the product or deduction by the customer.
RESEARCH AND DEVELOPMENT
Research and development costs relate primarily to the development of new
products and are expensed as incurred. Such expenses were $1,839, $1,369 and
$1,207 in 1999, 1998 and 1997, respectively.
39
ADVERTISING EXPENSES
The cost of advertising is expensed in the fiscal year in which the related
advertising takes place. Production and communication costs are expensed in the
period in which the related advertising begins running. Advertising expense for
1999, 1998 and 1997 was $54,764, $44,386 and $29,923, respectively. At November
30, 1999 and 1998, the Company reported $1,210 and $646, respectively, of
advertising paid for in 1999 and 1998 which will run or did run in the next
fiscal year. These amounts are included in other noncurrent assets in the
accompanying consolidated balance sheets.
40
NET INCOME PER COMMON SHARE
For the years ended November 30, 1999, 1998 and 1997, the weighted average
and dilutive potential common shares outstanding consisted of the following:
1999 1998 1997
------ ----- -----
Weighted average common shares
outstanding ................................. 9,747 9,374 8,793
Dilutive potential shares:
Stock options ............................. 277 332 207
Warrants .................................. -- 29 123
------ ----- -----
Weighted average and dilutive potential common
shares outstanding .......................... 10,024 9,735 9,123
====== ===== =====
FOREIGN CURRENCY TRANSLATION
Assets and liabilities of the Company's Canadian and U.K. subsidiaries are
translated to United States dollars at year-end exchange rates. Income and
expense items are translated at average rates of exchange prevailing during the
year. Translation adjustments are accumulated as a separate component of
shareholders' equity. Gains and losses which result from foreign currency
transactions are included in the accompanying consolidated statements of income.
USE OF ESTIMATES
The preparation of financial statements in conformity with generally
accepted accounting principles requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenue and expenses during the reporting
period. Actual results could differ from those estimates.
DERIVATIVE FINANCIAL INSTRUMENTS
The Company has entered into interest rate swap agreements from time to
time as a means of managing its interest rate exposure and not for trading
purposes. These agreements have the effect of converting a portion of the
Company's variable rate obligations to fixed rate obligations. Net amounts paid
or received are reflected as adjustments to interest expense. The Company is not
a party to any interest rate swap agreements at November 30, 1999.
41
CONCENTRATIONS OF CREDIT RISK
Financial instruments which subject the Company to concentrations of credit
risk consist primarily of accounts receivable and short-term cash investments.
The Company's exposure to credit risk associated with nonpayment of accounts
receivable is affected by conditions or occurrences within the retail industry.
As a result, the Company performs ongoing credit evaluations of its customers'
financial position but generally requires no collateral from its customers. The
Company's largest customer accounted for 19%, 17% and 16% of sales in 1999, 1998
and 1997, respectively. No other customer exceeded 10% of the Company's sales in
1999, 1998 or 1997. Short-term cash investments are placed with high
credit-quality financial institutions or in low risk, liquid instruments. No
losses have been experienced on such investments.
RECENT ACCOUNTING PRONOUNCEMENTS
In April 1998, the AICPA issued Statement of Position (SOP) 98-5,
"Reporting on the Costs of Start-Up Activities". SOP 98-5 requires costs of
start-up activities and organization costs to be expensed as incurred. This SOP
is effective for financial statements for fiscal years beginning after December
15, 1998. The Company will record the initial application of this SOP in
December 1999 as the cumulative effect of a change in accounting principle of
approximately $875.
In June 1998, the Financial Accounting Standards Board issued SFAS No.
133, "Accounting for Derivative Instruments and Hedging Activities." SFAS
No.133 established accounting and reporting standards requiring that every
derivative instrument (including certain derivative instruments embedded in
other contracts) be recorded in the balance sheet as either an asset or
liability measured at its fair value. SFAS No. 133 requires that changes in
the derivative's fair value be recognized currently in earnings unless
specific hedge accounting criteria are met. Special accounting for qualifying
hedges allow a derivative's gains and losses to offset related results on the
hedged item in the income statement, and requires that a company must
formally document, designate and assess the effectiveness of transactions
that receive hedge accounting. SFAS No. 137 delayed the effective date of
SFAS No. 133 until fiscal years beginning after June 15, 2000. A company may
also implement SFAS No.133 as of the beginning of any fiscal quarter after
issuance. SFAS No. 133 cannot be applied retroactively. SFAS No. 133 must be
applied to (a) derivative instruments and (b) certain derivative instruments
embedded in hybrid contracts that were issued, acquired or substantively
modified after December 31, 1997 (and, at the Company's election, before
January 1, 1999). SFAS No. 133 could increase volatility in earnings and
other comprehensive income, however, based on the Company's current and
anticipated level of derivative instruments and hedging activities, the
Company does not believe the impact would be material.
STOCK-BASED COMPENSATION
The Company accounts for its stock-based compensation plans under
Accounting Principles Board Opinion No. 25, "Accounting for Stock Issued to
Employees". Effective fiscal 1997, the Company adopted the disclosure option of
SFAS No. 123, "Accounting for Stock-Based Compensation".
RECLASSIFICATIONS
In June 1997, the Company terminated certain interest rate swap agreements
and in connection therewith recorded a $239 loss, net of tax, or $.03 per share,
42
as an extraordinary item. Subsequently, it was determined that the loss would
have been more appropriately classified as interest expense. The accompanying
consolidated income statement for fiscal 1997 has been revised to give effect
to this reclassification.
Certain other prior year amounts have also been reclassified to conform
to the current period's presentation.
(3) INVESTMENT IN ELCAT, INC.
As part of the consideration for the sale of the Company's specialty
chemicals division in 1995, the Company received 40,000 shares of 13.125%
cumulative, convertible preferred stock of Elcat, Inc. (the Elcat Preferred
Shares) having a total par value of $5,000.
In 1998, Elcat, Inc. (Elcat) redeemed 22,960 of these shares for $4,000
($2,870 par value and $1,130 accumulated dividends). The remaining 17,040 Elcat
Preferred Shares and accumulated dividends were redeemed in 1999 for $3,381.
($2,130 par value and $1,251 accumulated dividends).
43
(4) PENSION PLANS
The Company has a noncontributory defined benefit pension plan (the Plan)
which covers substantially all employees. The Plan provides benefits based upon
years of service and the employee's compensation. The Company's contributions
are based on computations by independent actuaries. Plan assets at November 30,
1999 and 1998 were invested primarily in United States government and agency
securities and corporate debt and equity securities.
Net periodic pension cost for the years ended November 30, 1999, 1998 and
1997 included the following components:
1999 1998 1997
------- ------- -----
Service cost (benefits earned during the period) $ 834 $ 661 $ 545
Interest cost on projected benefit obligation .. 747 739 741
Actual return on plan assets ................... 1,528 (3,226) (845)
Net amortization and deferral .................. (2,558) 2,677 365
------- ------- -----
Net pension cost ............................... $ 551 $ 851 $ 806
======= ======= =====
The change in the projected benefit obligation resulted from the following
components for the years ended November 30, 1999 and 1998:
1999 1998
-------- --------
Projected benefit obligation, beginning of year $ 11,275 $ 10,497
Service cost .................................. 834 661
Interest cost ................................. 747 739
Actuarial (gain) loss ......................... (1,636) 267
Benefits paid ................................. (1,157) (889)
-------- --------
Projected benefit obligation, end of year ..... $ 10,063 $ 11,275
======== ========
The change in plan assets resulted from the following components for the
years ended November 30, 1999 and 1998:
1999 1998
--------- --------
Fair value of plan assets, beginning of year $ 9,879 $ 6,471
Actual return on plan assets ............... (1,528) 3,226
Employer contribution ...................... 465 1,071
Benefits paid .............................. (1,157) (889)
------- -------
Fair value of plan assets, end of year ..... $ 7,659 $ 9,879
======= =======
44
The following table sets forth the funded status of the Plan as of November
30, 1999 and 1998:
1999 1998
----------- -----------
Plan assets at fair market value .................... $ 7,659 $ 9,879
Projected benefit obligation ........................ (10,063) (11,275)
-------- --------
Plan assets less than projected benefit obligation .. (2,404) (1,396)
Unrecognized net loss ............................... 1,806 1,043
Unrecognized prior service cost ..................... (98) (115)
Unrecognized initial asset .......................... (85) (227)
-------- --------
Pension liability recognized in balance sheets
at end of year .................................... $ (781) $ (695)
======== ========
The discount rates used in determining the actuarial present value of the
projected benefit obligation were 8.00% and 6.75% in 1999 and 1998,
respectively. The rates of increase in future compensation levels used were 4.5%
and 4.0% in 1999 and 1998, respectively. The expected long-term rate of return
on plan assets was 9.0% in 1999 and 1998.
The Company has a defined contribution plan covering substantially all
employees. Eligible participants can contribute up to 10% of their annual
compensation and receive a 25% matching employer contribution up to 6% of their
annual compensation. The defined contribution plan expense was $198, $148 and
$155 in 1999, 1998 and 1997, respectively.
(5) LONG-TERM DEBT
Long-term debt consisted of the following at November 30, 1999 and 1998:
1999 1998
-------- --------
Revolving line of credit payable to banks at variable
rates (7.59% at November 30, 1999) ...................................... $ 5,000 $ 2,000
Term loans payable to banks at variable rates
(7.58% weighted average at November 30,
1999) ................................................................... 55,600 40,514
8.875% Senior Subordinated Notes, due 2008, plus
unamortized premium of $265 for 1999 .................................... 275,265 200,000
12.75% Senior Subordinated Notes, due 2004, net of unamortized discount
of $460 for 1999 and $808 for 1998 ...................................... 34,085 48,843
-------- --------
Total long-term debt ...................................................... 369,950 291,357
Less: current maturities ................................................. 11,000 17,444
-------- --------
Total long-term debt, net of current maturities ........................... $358,950 $273,913
======== =======
On December 21, 1998, the Company refinanced its existing credit facilities
with $165,000 in senior secured credit facilities (the "Credit Facilities"). The
Credit Facilities were provided by a syndicate of commercial banks. The Credit
Facilities included a $50,000 revolving credit facility and a $115,000 term
loan. The Credit Facilities were used to refinance existing senior debt, to
45
finance the acquisition of the Thompson Medical brands (Note 12) and to
finance working capital and other general corporate needs.
Concurrent with the May 7, 1999 closing of a $75,000 note issuance
described below, the Company amended its Credit Facilities. The Credit
Facilities now consist of a $70,000 term loan maturing in quarterly
installments ranging from $2,000 to $4,750 through June 30, 2003 and a
$50,000 revolving credit facility maturing on December 21, 2003. The amended
Credit Facilities contain covenants, representations, warranties and other
agreements by the Company, including a maximum ratio of debt to EBITDA, as
defined, an annual limit on capital expenditures and a minimum level of net
worth, among other restrictions. For the year ended November 30, 1999, the
Company exceeded the allowed capital expenditures under the Credit
Facilities. The additional capital expenditures related primarily to the
implementation of the Company's new information technology system and
renovation of a new manufacturing facility. Subsequent to November 30, 1999,
the Company received a waiver from its lenders concerning this deficiency.
The Company has the option to pay interest based on either (i) the
greater of the prime rate or federal funds rate plus .5% or (ii) a floating
rate or Eurodollar interest rate option applicable to the term and revolving
line loans under the Credit Facilities. The prime rate and Eurodollar
interest rate options are based on a base rate plus a rate margin that
fluctuates on the basis of the Company's senior leverage ratio.
On March 24, 1998, the Company issued at par value $200,000 of 8.875%
Senior Subordinated Notes due 2008 (the 8.875% Notes). The proceeds of the
note offering were used to fund the BAN purchase (Note 12), repay revolving
bank indebtedness and provide additional working capital.
On May 7, 1999 the Company issued an additional $75,000 of its 8.875%
(priced to yield 8.8125%) Senior Subordinated Notes under its indenture
relating to the issuance of its $200,000 of 8.875% Notes on March 24, 1998.
The additional notes were issued under the Company's $250,000 shelf
registration statement filed on December 21, 1998 with the Securities and
Exchange Commission. The net proceeds from the issuance of the additional
notes were used to retire $41,500 of the then outstanding balance of the
Company's $115,000 term bank loan and the outstanding balance of $25,500 of
its revolving bank loan under the Credit Facilities.
The 8.875% Notes mature on April 1, 2008 and interest is payable
semi-annually on April 1 and October 1 of each year. The 8.875% Notes are
senior subordinated obligations of the Company and are subordinated in right
of payment to all existing and future senior debt of the Company. The 8.875%
Notes, which were registered under the Securities Act of 1933, are not
callable until April 1, 2003, after which they may be redeemed at the option
of the Company. Upon the occurrence of certain events constituting a change
of control, the holders of the 8.875% Notes may require the Company to
repurchase the 8.875% Notes at a purchase price equal to 101% of the
principal amount thereof, plus accrued and unpaid interest. The 8.875% Notes
are guaranteed by Signal Investment & Management Co., a wholly-owned
subsidiary of the Company.
The 8.875% Notes are issued under an indenture with an indenture
trustee, which restricts, among other things, the ability of the Company and
its subsidiaries to (i) incur additional indebtedness, (ii) pay dividends,
(iii) sell or issue capital stock of a subsidiary, (iv) create encumbrances
on the ability of any subsidiary to pay dividends or make other restricted
payments, (v) engage in certain transactions with affiliates, (vi) dispose of
certain assets, (vii) merge or consolidate with or into, or sell or otherwise
transfer all or substantially all their properties and assets as an entirety
to another person, or (viii) create additional liens.
In 1994, the Company issued $75,000 of 12.75% Senior Subordinated Notes
due 2004 (the 12.75% Notes) with five year warrants to purchase 417,182
shares of common stock (the Warrants). The 12.75% Notes consisted of 75,000
units, each consisting of $1.0 principal amount of the 12.75% Notes and a
warrant to purchase shares of the Company's common stock (Note 9). The price
of the 12.75% Notes was $73,967, or 98.6% of the original principal amount,
resulting in a discount of $1,033. The value assigned to the Warrants was
$955, resulting in a total original issue discount of $1,988. The proceeds of
the 12.75% Notes were used to repay amounts outstanding under a prior credit
agreement.
46
The 12.75% Notes mature on June 15, 2004, and interest is payable
semi-annually on June 15 and December 15 of each year. The 12.75% Notes are
senior subordinated obligations of the Company and are subordinated in right
of payment to all existing and future senior debt of the Company. The 12.75%
Notes, which were registered under the Securities Act of 1933, are callable
on June 15, 2001, after which they may be redeemed at the option of the
Company. Upon the occurrence of certain events constituting a change of
control, the holders of the 12.75% Notes may require the Company to
repurchase the 12.75% Notes at a purchase price equal to 101% of the
principal amount thereof, plus accrued and unpaid interest. The 12.75% Notes
are guaranteed by Signal Investment & Management Co., a wholly-owned
subsidiary of the Company.
The 12.75% Notes are issued under an indenture with an indenture
trustee. The indenture places on the Company restrictions similar to those
required under the terms of the indenture associated with the 8.875% Notes.
During 1999, 1998 and 1997, the Company prepaid previously outstanding
long-term debt with funds received from refinancings, the sale of CORNSILK
(Note 12), cash from operations, the redemption of the Elcat Preferred Shares
and the issuance of the 8.875% Notes. In connection with the repayment of
those borrowings, the Company incurred extraordinary losses, net of income
taxes, in 1999, 1998 and 1997 of $2,385, $2,859 and $1,131, respectively, or
$.24, $.29 and $.12 per diluted share, respectively. These losses related to
the write-off of debt issuance and other deferred financing costs and the
premiums paid on the retirement of the 12.75% Notes.
Future maturities of long-term debt are as follows:
2000........................ $ 11,000
2001........................ 14,250
2002........................ 17,250
2003........................ 13,100
2004........................ 39,545
Thereafter................... 275,000
---------
370,145
Less: net unamortized discount (195)
---------
$ 369,950
---------
---------
The 2004 maturities include the amount outstanding under the revolving
line of credit which was $5,000 as of November 30, 1999 and the remaining
balance of the 12.75% Notes.
Cash interest payments during 1999, 1998 and 1997 were $34,822, $23,669
and $15,259, respectively, net of $255 capitalized in 1999.
47
(6) DERIVATIVE FINANCIAL INSTRUMENTS
On July 21, 1997, the Company entered into two interest rate swap
agreements with a financial institution in notional amounts of $40,000 and
$5,000. The Company entered into these agreements as hedges on its variable
rate debt and not for trading purposes. The swaps were scheduled to expire
July 22, 2002. In connection with the May 1999 refinancing of its long-term
debt, the Company terminated these agreements, which resulted in a $1,151
loss. This loss has been deferred by the Company and is being written off as
interest expense over the remaining life of the agreements. In fiscal 1999
$213 of this loss was charged to interest expense.
(7) FAIR VALUE OF FINANCIAL INSTRUMENTS
Unless otherwise indicated elsewhere in the notes to the consolidated
financial statements, the carrying value of the Company's financial
instruments approximates fair value.
At November 30, 1999, the estimated fair values of the revolving line of
credit and the term loan payable to banks approximate the carrying amounts of
such debt because the interest rates change with market interest rates.
At November 30, 1999, the estimated fair value of the 12.75% Notes
exceeded their carrying value by approximately $2,500, while the carrying
value of the 8.875% Notes exceeded their estimated fair value by
approximately $26,100. The fair value was estimated based on quoted market
prices for the same or similar issues.
48
(8) INCOME TAXES
The provision for income taxes from income before extraordinary loss
includes the following components for the years ending November 30, 1999,
1998 and 1997:
1999 1998 1997
------- ------- -------
Current:
Federal .......................... $ 8,115 $ 8,034 $ 2,639
State ............................ 954 459 234
Deferred ........................... 4,598 2,351 974
------- ------- -------
$13,667 $10,844 $ 3,847
======= ======= =======
Deferred income tax assets and liabilities reflect the impact of
temporary differences between the amounts of assets and liabilities for
financial reporting and income tax reporting purposes. Temporary differences
and carryforwards which give rise to deferred tax assets and liabilities at
November 30, 1999 and 1998 are as follows:
1999 1998
------- -------
Deferred tax assets:
Allowances and accruals .......... $ 1,930 $ 2,303
Accrued promotional expenses ..... 4,587 1,316
Accrued postretirement health care
benefits ....................... 583 558
Other ............................ 1,550 643
------- -------
Gross deferred tax assets ...... 8,650 4,820
------- -------
Deferred tax liabilities:
Depreciation and amortization .... 16,008 7,829
Prepaid advertising .............. 331 252
Inventory ........................ 196 196
Other ............................ 490 320
------- -------
Gross deferred tax liabilities . 17,025 8,597
------- -------
Net deferred liability ....... $ 8,375 $ 3,777
======= =======
49
The difference between the provision for income taxes and the amount
computed by multiplying income before income taxes and extraordinary loss by
the U.S. statutory rate for the years ended November 30, 1999, 1998 and 1997
is summarized as follows:
1999 1998 1997
-------- -------- --------
Expected tax provision ....................... $ 12,673 $ 10,140 $ 3,837
Dividend exclusion benefit ................... (69) (85) (178)
State income taxes, net of federal
income tax benefit ......................... 1,327 1,076 402
Other, net ................................... (264) (287) (214)
-------- -------- --------
$ 13,667 $ 10,844 $ 3,847
======== ======== ========
Income taxes paid in 1999, 1998 and 1997 were $8,171, $1,980 and $2,162,
respectively. The Company received income tax refunds of $23, $350 and $2,719
during 1999, 1998 and 1997, respectively
(9) SHAREHOLDERS' EQUITY
STOCK OPTIONS
The Company's 1993 Non-Statutory Stock Option Plan provides for issuance
of up to 350,000 shares of common stock to key employees. In addition, the
Company's 1994 Non-Statutory Stock Option Plan and the 1994 Non-Statutory
Stock Option Plan for Non-Employee Directors provide for the issuance of up
to 350,000 and 80,000 shares, respectively, of common stock. The Company's
1998 Non-Statutory Stock Option Plan provides for issuance of up to 700,000
shares of common stock to key employees, while the 1999 Non-Statutory Stock
Option Plan for Non-Employee Directors allows issuance of up to 100,000
shares of common stock. Options vest ratably over four years and are
exercisable for a period of up to ten years from the date of grant.
For SFAS No. 123 purposes, the fair value of each option grant has been
estimated as of the date of grant using the Black-Scholes option-pricing
model with the following weighted average assumptions for grants in 1999, 1998
and 1997: expected dividend yield of 0%, expected volatility of 58%, 51% and
49%, risk-free interest rates of 4.81%, 5.42% and 6.48% and expected lives of
6 years.
50
Had compensation expense for stock option grants been determined based
on the fair value at the grant dates consistent with the method prescribed by
SFAS No. 123, the Company's net income and net income per share would have
been adjusted to the pro forma amounts for the years ended November 30, 1999,
1998 and 1997 as indicated below:
1999 1998 1997
---------- ---------- ----------
Net income:
As reported ............... $ 20,156 $ 15,269 $ 5,885
Pro forma ................. $ 18,980 $ 14,599 $ 5,683
Net income per share, basic:
As reported ............... $ 2.07 $ 1.63 $ 0.67
Pro forma ................. $ 1.95 $ 1.56 $ 0.65
Net income per share, diluted:
As reported ............... $ 2.01 $ 1.57 $ 0.65
Pro forma ................. $ 1.89 $ 1.50 $ 0.62
51
A summary of the activity of stock options during 1999, 1998, and 1997
is presented below (shares in thousands):
1999 1998 1997
-------------------- ------------------- --------------------
Weighted Weighted Weighted
Shares Average Shares Average Shares Average
Under Exercise Under Exercise Under Exercise
Option Price Option Price Option Price
------ --------- ------ -------- ------ ---------
Outstanding at beginning of
year ....................... 762 $ 11.17 584 $ 6.75 613 $ 6.39
Granted .................. 136 39.38 470 13.89 91 9.01
Exercised ................ (46) 7.50 (292) 6.70 (120) 6.65
Cancelled ................ (3) 14.71 -- -- -- --
------- --------- -------- --------- -------- --------
Outstanding at end of year ... 849 $ 15.92 762 $ 11.17 584 $ 6.75
======= ========= ======== ========= ======== ========
Options exercisable at year-
end ........................ 239 $ 10.24 96 $ 7.48 262 $ 7.43
======= ========= ======== ========= ======== ========
Weighted average fair value of
options granted .............. $ 23.25 $ 7.69 $ 5.24
========= ========= ========
Compensation expense for stock option grants with exercise prices below
the market price at the date of grant is recognized ratably over the vesting
period. In 1998, options were granted to purchase 419,000 shares, which were
at market price on the date of approval by the board of directors but at
prices below the market price on the date of shareholder approval.
Compensation expense recorded for this grant was $525 in 1999 and $350 in
1998.
A summary of the exercise prices for options outstanding under the
Company's stock-based compensation plans at November 30, 1999, is presented
below (shares in thousands):
Weighted Weighted
Weighted Average Average Exercise
Exercise Price Shares Under Average Exercise Remaining Life in Shares Price of Shares
Range Option Price Years Exercisable Exercisable
--------------- ------------ ----------------- ----------------- ----------- ------------------
$ 4.63 - $ 5.25 120 $ 4.87 6.2 47 $ 4.86
$ 7.13 - $ 9.50 126 8.38 5.7 80 8.30
$13.50 - $18.00 461 13.77 8.2 111 13.78
$25.63 - $38.00 17 29.94 8.4 1 25.78
$39.81 125 39.81 9.2 -- --
----------- ----------- ----------- ------------ ---------
Total 849 $ 15.92 7.7 239 $ 10.24
=========== =========== =========== =========== ========
52
PREFERRED SHARES
The Company is authorized to issue up to 1,000,000 preferred shares in
series and with rights established by the board of directors. At November 30,
1999 and 1998, no shares of any series of preferred stock were issued and
outstanding.
EMPLOYEE STOCK OWNERSHIP PLAN
Effective June 1, 1989, the Company established an Employee Stock
Ownership Plan providing for the issuance of up to 360,000 shares of the
Company's common stock. At November 30, 1999, no contributions had been made
to the plan.
COMMON STOCK WARRANTS
During 1999, 22,400 warrants were exercised to acquire 131,196 shares.
During 1998, 35,568 warrants were exercised to acquire 208,337 shares. At
November 30, 1999, no warrants were outstanding since the right to exercise
the remaining outstanding warrants expired on August 16, 1999.
STOCK BUYBACK
In 1999 the Company redeemed and returned to unissued 172,500 shares of
its common stock, without par value, for $3,912. As of November 30, 1999 the
remaining amount of repurchase authorization from the Company's board of
directors is $6,088. Under the authorization, purchases may be made from time
to time in either open market or privately negotiated transactions.
SHAREHOLDER RIGHTS PLAN
On January 26, 2000, the Company's board of directors adopted a new
Shareholder Rights Plan. Under the plan, Rights were constructively
distributed as a dividend at the rate of one Right for each share of common
stock, without par value, of the Company held by shareholders of record as
of the close of business on February 11, 2000. Each Right initially will
entitle shareholders to buy one one-hundredth of a share of a new Series A
Junior Participating Preferred Stock at an exercise price of $90.00 per
Right, subject to adjustment. The Rights generally will be exercisable only
if a person or group acquires beneficial ownership of 15% or more of the
Company's common stock. The Rights will expire on February 11, 2010.
(10) CONTINGENCIES
GENERAL LITIGATION
The Company has been named as a defendant in a lawsuit brought by the
Center for Environment Health (CEH) contending that the Company violated the
California Safe Drinking Water and Toxic Enforcement Act of 1998 (Proposition
65) by selling to California consumers without a warning topical skin care
products containing zinc oxide which in turn contains lead. On December 30,
1999, Chattem was sent a notice of intent to sue letter from CEH alleging
that Chattem had violated Proposition 65 because zinc oxide allegedly also
contains cadmium. The lawsuit contends that the purported failure to comply
with Proposition 65 requirements also constitutes a violation of the
California Business & Profession Code Section 1700, et seq. Violations of
either Proposition 65 or Business & Profession Code Section 1700, et seq.
render a defendant liable for civil penalties of up to $2.5 per day per
violation.
The Company has also been named as a defendant in a lawsuit filed in San
Francisco Superior Court on December 29, 1999, Johnson et al. v.
Bristol-Myers Squibb Co., et al., Case No. 308872. This is a putative class
action brought by two named plaintiffs on behalf of the general public in
California, against the same entities that are defendants in the CEH lawsuit.
As with the CEH lawsuit, the Johnson lawsuit alleges that Chattem violated
Proposition 65 by selling to California consumers without a warning topical
skin care product containing zinc oxide which in turn contains lead. The
lawsuit does not assert claims directly under Proposition 65, but asserts
that the alleged failure to comply with Proposition 65 gives rise to claims
under California's Business and Professions Code Sections 17200 et seq., and
17500 et seq., and the Civil Code Section 1750 et seq. The lawsuit seeks
injunctive and equitable relief, restitution, the disgorgement of allegedly
wrongfully obtained revenues, and damages.
The Company intends to vigorously defend these claims. These actions
have only recently been filed, however, and it is not possible at this time
to determine the outcome of these matters or the effect of their resolution on
the Company's financial position or operating results. Management believes
that the Company's defenses have merit; however, there can be no assurance
that the Company will be successful in its defense or that these lawsuits
will not have a material adverse effect on the Company's results of
operations for some period or on the Company's financial position.
53
In February 1999 a complaint was filed against the Company by Genderm
Corporation ("Genderm") in the U.S. District Court for the District of
Arizona. The complaint alleged, among other things, that the formulations of
CAPZASIN-P, CAPZASIN-HP and ICY HOT Arthritis Therapy Gel infringed U.S.
Patent 4,485,450 owned by Joel Bernstein, M.D. and licensed to Genderm (the
"Patent"). The complaint requested injunctive relief, compensatory and treble
damages, costs and attorneys fees. A hearing on the preliminary injunction
was held on April 13-14, 1999. On May 6, 1999 U.S. District Court for the
District of Arizona held that Genderm had carried its burden of proving a
substantial likelihood of success and ultimately showing that the Patent was
infringed and issued a preliminary injunction prohibiting the Company from
shipping CAPZASIN-P cream, CAPZASIN-HP cream and ICY HOT Arthritis Therapy
Gel. Following the issuance of the preliminary injunction, the Company
reached a settlement with Genderm pursuant to which the Company made a single
payment of $750 in 1999 in exchange for the dismissal of the complaint and a
fully paid license to use the Patent until its expiration. The settlement
cost was recorded as a settlement of a pre-acquisition contingency.
Other claims, suits and complaints arise in the ordinary course of the
Company's business involving such matters as patents and trademarks, product
liability, environmental matters and other alleged injuries or damage. The
outcome of such litigation cannot be predicted, but, in the opinion of
management, based in part upon the opinion of counsel, all such pending
matters are without merit or are of such kind or involve such amounts as
would not have a material adverse effect on the consolidated operating
results or financial position of the Company if disposed of unfavorably.
REGULATORY
The manufacturing, processing, formulation, packaging, labeling and
advertising of the Company's products are subject to regulation by federal
agencies, including the United States Food and Drug Administration (FDA). As
part of its regulatory authority, the FDA may periodically conduct audits of
the physical facilities, machinery, processes and procedures which the
Company uses to manufacture products. In December 1998, the FDA conducted an
audit of the Company's manufacturing facility in Chattanooga, Tennessee. The
FDA issued a report citing certain processes and procedures it requires the
Company to change or improve. The Company has responded to the FDA's report
and believes that it has complied with the requirements of the report. No
further contact by the FDA has been made to date, but the Company expects a
follow-up visit by FDA personnel in the future.
YEAR 2000 (unaudited)
The Company has successfully completed the replacement of its previous
information technology (IT) systems with those that are year 2000 compliant.
The cost of the new IT systems to date is approximately $3,230, which has
been capitalized.
To date the Company has experienced no major problems with its
implementation, nor has it encountered any unusual situations with its
principal customers and suppliers in connection with their year 2000 IT
systems' compliance.
However, if unanticipated problems arise in the future with regard to
year 2000 compliance with the Company's new IT systems or those of its
principal customers and suppliers, the Company's business could be adversely
affected.
54
(11) SUPPLEMENTAL FINANCIAL INFORMATION
Inventories consisted of the following at November 30, 1999 and 1998:
1999 1998
--------- --------
Raw materials and work in process ......................... $ 12,542 $ 7,903
Finished goods ............................................ 17,190 14,113
Excess of current cost over LIFO value .................... (1,914) (2,410)
--------- ---------
Total inventories ....................................... $ 27,818 $ 19,606
========= =========
International inventories included above, valued on a lower of FIFO cost
or market at November 30, 1999 and 1998, were $2,611 and $3,004, respectively.
Property, plant and equipment consisted of the following at November 30,
1999 and 1998:
1999 1998
--------- --------
Land ...................................................... $ 140 $ 140
Buildings and improvements ................................ 3,836 3,434
Machinery and equipment ................................... 34,894 29,678
Construction in progress................................... 6,813 2,900
Less -- accumulated depreciation .......................... (19,931) (18,006)
--------- --------
Property, plant and equipment, net ...................... $ 25,752 $ 18,146
========= ========
Accrued liabilities consisted of the following at November 30, 1999 and
1998:
1999 1998
--------- --------
Accrued interest expense .................................. $ 6,326 $ 5,969
Salaries, wages and commissions ........................... 2,098 2,850
Promotion expense ......................................... 15,880 8,896
Product acquisitions ...................................... 2,999 3,290
Accrued pension benefits .................................. 781 700
Accrued royalties.......................................... 56 2,889
Other...................................................... 4,007 5,615
-------- ---------
Total accrued liabilities................................ $ 32,147 $ 30,209
======== =========
55
(12) ACQUISITION AND SALE OF BRANDS
On December 21, 1998, the Company acquired the DEXATRIM, SPORTSCREME,
ASPERCREME, CAPZASIN-P, CAPZASIN-HP and ARTHRITIS HOT brands from Thompson
Medical Company, Inc. (the "Thompson Medical Brands") for $95,000. The
purchase price consisted of $90,000 cash and 125,500 shares of the Company's
common stock. The cash portion of the purchase price was financed by a new
senior credit facility. The purchase price of $95,000 was allocated $3,493 to
inventory and $91,507 to trademarks and other product rights which were
assigned a useful life of 40 years.
On March 24, 1998, the Company acquired the BAN line of antiperspirant
and deodorant products from Bristol-Myers Squibb Company for a purchase price
of approximately $165,000 and assumed liabilities of $8,000. The Company
acquired the BAN trademarks, formulae, certain patents pertaining to
antiperspirant/deodorant technology, technical information, inventory,
manufacturing equipment and packaging related assets used in the manufacture
of BAN, but not the right to sell BAN in Japan. The purchase price of
$173,000 was allocated $8,200 to inventory and $164,800 to trademarks and
other product rights which were assigned a useful life of 40 years.
The following unaudited consolidated pro forma information assumes the
acquisition of BAN and the Thompson Medical brands and their related
long-term borrowings had occurred on December 1, 1997:
PRO FORMA CONSOLIDATED RESULTS OF OPERATIONS (UNAUDITED)
1999 1998
------------ ------------
Net Sales ......................... $ 302,631 $ 294,243
Income before extraordinary loss 23,131 22,768(1)
Net Income ........................ 20,746 19,909(1)
Earnings per share (basic):
Income before extraordinary loss 2.37 2.40
Net income ...................... 2.13 2.09
Earnings per share (diluted):
Income before extraordinary loss 2.31 2.31
Net income ...................... 2.07 2.02
(1) Includes gain on the sale of CORNSILK.
The pro forma consolidated results of operations include adjustments to give
effect to amortization of intangible assets, interest expense on acquisition
debt and certain other adjustments, together with related income tax effects.
The pro forma information is for comparative purposes only and does not purport
to be indicative of the combined results that would have occurred had the
acquisition and borrowings occurred at the beginning of the periods presented,
or indicative of the results that may occur in the future.
56
On May 12, 1998, the Company sold the CORNSILK oil control makeup brand
to Del Laboratories, Inc. for $10,750, plus inventories and the assumption of
certain liabilities. The Company sold, at a gain of $9,548, CORNSILK
trademarks, formulae, technical information, inventory and other related
assets but will continue to operate the CORNSILK business in the United
Kingdom pursuant to a licensing agreement. The Company used the net proceeds
from the sale to reduce bank indebtedness.
On June 26, 1997, the Company purchased certain assets of Sunsource
International, Inc. and an affiliated company (SUNSOURCE) including the
exclusive worldwide rights to five leading branded dietary supplement
products. The purchase price for the trademarks, inventory and receivables
was approximately $32,000, net of certain assumed liabilities. The $32,000
was allocated $1,786 to inventory and receivables and $30,214 to trademarks
and other product rights which were assigned a useful life of 40 years.
Financing of the SUNSOURCE acquisition was provided by an expansion of the
Company's senior bank credit agreement and the issuance of 300,000 shares of
Chattem, Inc. common stock to SUNSOURCE. Additional payments were scheduled
to be earned by SUNSOURCE over a six year period from the date of closing if
sales exceed certain levels as defined in the purchase agreement. In 1998 the
Company paid the former owners of SUNSOURCE $2,500 and forgave $5,625 of
amounts due the Company, in exchange for a 50% reduction in any future
additional payments under the purchase agreement. In 1999, the Company paid
the former owners of SUNSOURCE $1,650 and issued 2,582 shares of its common
stock in exchange for cancellation of the right to receive any future
additional payments under the purchase agreement. The 1998 and 1999
considerations were capitalized as additional purchase price.
57
(13) ACCRUED POSTRETIREMENT HEALTH CARE BENEFITS
The Company maintains certain postretirement health care benefits for
eligible employees. Employees become eligible for these benefits if they meet
certain age and service requirements. The Company pays a portion of the cost
of medical benefits for certain retired employees over the age of 65.
Effective January 1, 1993, the Company's contribution is a service-based
percentage of the full premium. The Company pays these benefits as claims are
incurred.
Net periodic postretirement health care benefits cost for the years
ended November 30, 1999, 1998 and 1997, included the following components:
1999 1998 1997
----- ----- -----
Service cost (benefits earned during the period) $ 31 $ 19 $ 29
Interest cost on accumulated postretirement
benefits obligation .......................... 76 82 115
Amortization of net loss (gain) ................ (10) (18) 2
---- ---- ----
Net periodic postretirement benefits cost ...... $ 97 $ 83 $ 146
===== ===== =====
The change in the accumulated benefit obligation resulted from the
following components for the years ended November 30, 1999 and 1998:
1999 1998
--------- ----------
Accumulated benefit obligation, beginning of
year..................................................... $ 1,220 $ 1,114
Service cost............................................... 31 19
Interest cost.............................................. 76 82
Effect of plan amendment................................... 174 --
Actuarial (gain) loss...................................... (443) 92
Benefits paid.............................................. (35) (87)
---------- ----------
Accumulated benefit obligation, end of year................ $ 1,023 $ 1,220
========== =========
The following table sets forth the funded status of the plan at November
30, 1999 and 1998:
1999 1998
--------- ---------
Accumulated benefit obligation............................. $ 1,023 $ 1,220
Fair value of plan assets.................................. -- --
--------- ---------
Funded status............................................... (1,023) (1,220)
Unrecognized prior service cost............................ 159 --
Unrecognized actuarial gain ............................... (630) (210)
--------- ---------
Accrued postretirement benefits cost....................... $ (1,494) $ (1,430)
========= =========
For measurement purposes, a 6.0% annual rate of increase in the per
capita cost of covered health care benefits was assumed in 1999 and 1998. The
weighted-average discount rate used in determining the accumulated
postretirement benefit obligation was 6.75% and 8.0% at November 30, 1999 and
1998, respectively. Due to premium caps in place which limit the Company's
expense, a 1% increase in the assumed health care cost trend rate would not
affect the accumulated postretirement benefit obligation as of November 30,
1999 or the aggregate of the service and interest cost components of the net
annual postretirement benefit cost for the year ended November 30, 1999.
58
(14) COMPREHENSIVE INCOME
Comprehensive income consisted of the following components for the years
ended November 30, 1999, 1998 and 1997, respectively:
1999 1998 1997
-------- -------- --------
Net income ....................... $ 20,156 $ 15,269 $ 5,885
Other-foreign currency translation
adjustment ..................... (15) (30) 37
-------- -------- --------
Total ........................ $ 20,141 $ 15,239 $ 5,922
======== ======== ========
(15) PRODUCT AND GEOGRAPHICAL SEGMENT INFORMATION
The Company operates in two primary segments that are based on the
different types of products offered. The OTC health care segment includes
medicated skin care products, topical analgesics, internal analgesics, lip
care, appetite suppressant and dietary supplement products. The toiletries
and skincare segment includes antiperspirants and deodorants, facial cleaners
and masques and seasonal products. The accounting policies of the segments
are the same as those described in the summary of significant accounting
policies. Certain assets, including the majority of property, plant and
equipment and deferred tax assets are not allocated to the identifiable
segments.
The Company's largest customer accounted for 11%, 7% and 11% of OTC
health care net sales and 8%, 10% and 5% of toiletries and skincare net sales
in 1999, 1998 and 1997, respectively.
In the table below the following items are included in the indicated
captions:
Variable contribution margin: net sales less variable cost of goods
sold, advertising, promotion, market research, freight out, sales
commissions, royalties, bad debts and inventory obsolescence. The Company
evaluates the performance of its operating segments based on variable
contribution margins.
Depreciation and amortization: amortization of the cost of trademarks
and other product rights with unallocated depreciation and other
amortization expense being shown under the "Not Classified" caption.
Identifiable/total assets: primarily identified unamortized cost of
trademarks and other product rights and total inventory cost with the
remainder of total assets being shown under the "Not Classified" heading.
59
Product Classifications
-----------------------------------------------
OTC Toiletries
Health and Not
Total Care Skincare Classified
------ ------- ----------- ----------
1999:
Net sales ...................... $298,142 $172,256 $125,650 $ 236
Variable contribution margin ... 116,356 68,582 47,429 345
Depreciation and amortization .. 15,064 5,087 4,935 5,042
Identifiable assets/total assets 491,624 198,189 194,241 99,194
1998:
Net sales ...................... $220,064 $117,309 $101,854 $ 901
Variable contribution margin ... 81,815 42,978 38,488 349
Depreciation and amortization .. 9,827 2,753 3,567 3,507
Identifiable assets/total assets 369,012 101,509 198,231 69,272
1997:
Net sales ...................... $143,235 $ 95,276 $ 46,041 $ 1,918
Variable contribution margin ... 55,061 40,972 13,710 379
Depreciation and amortization .. 6,381 2,227 780 3,374
Identifiable assets/total assets 178,744 94,743 32,184 51,817
The reconcilement of variable contribution margin, as shown above, to
income before income taxes and extraordinary loss is as follows:
1999 1998 1997
--------- --------- ---------
Variable contribution margin .......................... $ 116,356 $ 81,815 $ 55,061
Less divisional and corporate overhead not allocated to
product groups ...................................... 44,155 36,596 29,558
--------- --------- ---------
Income from operations ................................ 72,201 45,219 25,503
--------- --------- ---------
Other income (expense):
Interest expense .................................... (36,572) (26,676) (16,319)
Investment and other income, net .................... 579 881 1,679
Gain on product divestiture ......................... -- 9,548 --
--------- --------- ---------
Total other income (expense) ........................ (35,993) (16,247) (14,640)
--------- --------- ---------
Income before income taxes and extraordinary loss ..... $ 36,208 $ 28,972 $ 10,863
========= ========= =========
60
Geographical segment information is as follows for the years ended
November 30, 1999, 1998 and 1997:
1999 1998 1997
-------- -------- --------
Net Sales:
Domestic ......... $276,632 $199,811 $128,024
International(1).. 21,510 20,253 15,211
-------- -------- --------
Total .......... $298,142 $220,064 $143,235
======== ======== ========
Long-Lived Assets(2):
Domestic ......... $381,694 $289,972 $115,413
International .... 353 471 547
-------- -------- --------
Total .......... $382,047 $290,443 $115,960
======== ======== ========
(1) International sales includes export sales from U.S. operations.
(2) Consists of book value of property, plant, equipment, trademarks and
other product rights.
(16) CONSOLIDATING FINANCIAL STATEMENTS
The condensed consolidating financial statements, for the dates or
periods indicated, of Chattem, Inc. ("Chattem"), Signal Investment &
Management Co. ("Signal"), the guarantor of the long-term debt of Chattem,
and the non-guarantor wholly-owned subsidiary companies of Chattem are
presented below. Signal is a wholly-owned subsidiary of Chattem; the
guarantee of Signal is full and unconditional and joint and several.
61
Note 16
CHATTEM, INC. AND SUBSIDIARIES
CONSOLIDATING BALANCE SHEETS
NOVEMBER 30, 1999
(Unaudited and in thousands)
NON-GUARANTOR
SUBSIDIARY ELIMINATIONS
CHATTEM SIGNAL COMPANIES DR, (CR.) CONSOLIDATED
------- ------ ------------- ------------- ------------
ASSETS
CURRENT ASSETS:
Cash and cash equivalents ................ $ 550 $ 16 $ 1,742 $ -- $ 2,308
Accounts receivable, less allowance for
doubtful accounts of $900 .............. 50,541 -- 4,491 -- 55,032
Deferred income taxes .................... 6,951 -- -- -- 6,951
Inventories .............................. 25,519 -- 2,299 -- 27,818
Prepaid expenses and other current assets 739 -- 190 -- 929
--------- --------- --------- --------- ---------
Total current assets ................... 84,300 16 8,722 -- 93,038
--------- --------- --------- --------- ---------
PROPERTY, PLANT AND EQUIPMENT,
NET .................................... 25,399 -- 353 -- 25,752
--------- --------- --------- --------- ---------
OTHER NONCURRENT ASSETS:
Patents, trademarks and other purchased
product rights, net .................... 5,533 350,762 -- -- 356,295
Debt issuance costs, net ................. 11,469 -- -- -- 11,469
Investment in subsidiaries ............... 9,930 -- -- (9,930) --
Other .................................... 4,709 -- 361 -- 5,070
--------- --------- --------- --------- ---------
Total other noncurrent assets .......... 31,641 350,762 361 (9,930) 372,834
--------- --------- --------- --------- ---------
TOTAL ASSETS ......................... $ 141,340 $ 350,778 $ 9,436 $ (9,930) $ 491,624
========= ========= ========= ========= =========
LIABILITIES AND SHAREHOLDERS' EQUITY
CURRENT LIABILITIES:
Current maturities of long-term debt ..... $ 11,000 $ -- $ -- $ -- $ 11,000
Accounts payable ......................... 18,053 -- 520 -- 18,573
Payable to bank .......................... 4,905 -- -- -- 4,905
Accrued liabilities ...................... 30,630 -- 1,517 -- 32,147
--------- --------- --------- --------- ---------
Total current liabilities .............. 64,588 -- 2,037 -- 66,625
--------- --------- --------- --------- ---------
LONG-TERM DEBT, less current maturities .... 358,950 -- -- -- 358,950
--------- --------- --------- --------- ---------
DEFERRED INCOME TAXES ...................... 2,776 12,550 -- -- 15,326
--------- --------- --------- --------- ---------
OTHER NONCURRENT LIABILITIES ............... 2,022 -- -- -- 2,022
--------- --------- --------- --------- ---------
INTERCOMPANY ACCOUNTS ...................... (334,574) 336,612 (2,038) -- --
--------- --------- --------- --------- ---------
SHAREHOLDERS' EQUITY:
Preferred shares, without par value,
authorized 1,000, none issued .......... -- -- -- -- --
Common shares, without par value,
authorized 50,000, issued 9,707 ........ 2,021 2 9,928 9,930 2,021
Paid-in surplus .......................... 72,850 -- -- -- 72,850
Accumulated deficit ...................... (26,819) 1,614 401 -- (24,804)
--------- --------- --------- --------- ---------
Total .................................. 48,052 1,616 10,329 9,930 50,067
Cumulative other comprehensive income -
Foreign currency translation adjustment . (474) -- (892) -- (1,366)
--------- --------- --------- --------- ---------
Total shareholders' equity ............. 47,578 1,616 9,437 9,930 48,701
--------- --------- --------- --------- ---------
TOTAL LIABILITIES AND
SHAREHOLDERS' EQUITY .............. $ 141,340 $ 350,778 $ 9,436 $ 9,930 $ 491,624
========= ========= ========= ========= =========
62
Note 16
CHATTEM, INC. AND SUBSIDIARIES
CONSOLIDATING BALANCE SHEETS
NOVEMBER 30, 1998
(Unaudited and in thousands)
NON-GUARANTOR
SUBSIDIARY ELIMINATIONS
CHATTEM SIGNAL COMPANIES DR, (CR.) CONSOLIDATED
------- ------ ------------- ------------- ------------
ASSETS
CURRENT ASSETS:
Cash and cash equivalents ................ $ (95) $ 11 $ 2,160 $ -- $ 2,076
Accounts receivable, less allowance for
doubtful accounts of $775 .............. 32,920 -- 3,661 -- 36,581
Deferred income taxes .................... 3,049 -- -- -- 3,049
Inventories .............................. 16,607 -- 2,999 -- 19,606
Prepaid expenses and other current assets 93 415 276 -- 784
--------- --------- --------- --------- ---------
Total current assets ................... 52,574 426 9,096 -- 62,096
--------- --------- --------- --------- ---------
PROPERTY, PLANT AND EQUIPMENT, NET ......... 17,675 -- 471 -- 18,146
--------- --------- --------- --------- ---------
OTHER NONCURRENT ASSETS:
Investment in Elcat, Inc. ................ 3,102 -- -- -- 3,102
Patents, trademarks and other purchased
product rights, net .................... 4,409 267,817 -- -- 272,226
Debt issuance costs, net ................. 10,091 -- -- -- 10,091
Investment in subsidiaries ............... 9,930 -- -- (9,930) --
Other .................................... 2,979 -- 372 -- 3,351
--------- --------- --------- --------- ---------
Total other noncurrent assets .......... 30,511 267,817 372 (9,930) 288,770
--------- --------- --------- --------- ---------
TOTAL ASSETS ......................... $ 100,760 $ 268,243 $ 9,939 $ (9,930) $ 369,012
========= ========= ========= ========= =========
LIABILITIES AND SHAREHOLDERS' EQUITY
CURRENT LIABILITIES:
Current maturities of long-term debt ..... $ 17,444 $ -- $ -- $ -- $ 17,444
Accounts payable ......................... 12,090 -- 643 -- 12,733
Payable to bank .......................... 1,026 -- -- -- 1,026
Accrued liabilities ...................... 28,963 20 1,226 -- 30,209
--------- --------- --------- --------- ---------
Total current liabilities .............. 59,523 20 1,869 -- 61,412
--------- --------- --------- --------- ---------
LONG-TERM DEBT, less current maturities .... 273,913 -- -- -- 273,913
--------- --------- --------- --------- ---------
DEFERRED INCOME TAXES ...................... 1,085 5,741 -- -- 6,826
--------- --------- --------- --------- ---------
OTHER NONCURRENT LIABILITIES ............... 2,110 -- -- -- 2,110
--------- --------- --------- --------- ---------
INTERCOMPANY ACCOUNTS ...................... (259,582) 259,661 (79) -- --
--------- --------- --------- --------- ---------
SHAREHOLDERS' EQUITY:
Preferred shares, without par value,
authorized 1,000, none issued .......... -- -- -- -- --
Common shares, without par value,
authorized 20,000, issued 9,574 ........ 1,994 2 9,928 9,930 1,994
Paid-in surplus .......................... 69,068 -- -- -- 69,068
Accumulated deficit ...................... (46,846) 2,819 (933) -- (44,960)
--------- --------- --------- --------- ---------
24,216 2,821 8,995 9,930 26,102
Cumulative other comprehensive income -
Foreign currency translation adjustment . (505) -- (846) -- (1,351)
--------- --------- --------- --------- ---------
Total shareholders' equity ............. 23,711 2,821 8,149 9,930 24,751
--------- --------- --------- --------- ---------
TOTAL LIABILITIES AND
SHAREHOLDERS' EQUITY ............... $ 100,760 $ 268,243 $ 9,939 $ 9,930 $ 369,012
========= ========= ========= ========= =========
63
Note 16
CHATTEM, INC. AND SUBSIDIARIES
CONSOLIDATING STATEMENTS OF INCOME
FOR THE YEAR ENDED NOVEMBER 30, 1999
(Unaudited and in thousands)
NON-GUARANTOR
SUBSIDIARY ELIMINATIONS
CHATTEM SIGNAL COMPANIES DR, (CR.) CONSOLIDATED
------- ------ --------- -------------- ------------
NET SALES ........................... $ 280,686 $ -- $ 17,456 $ -- $ 298,142
--------- --------- ---------- --------- ---------
COSTS AND EXPENSES:
Cost of sales ..................... 69,810 -- 5,802 -- 75,612
Advertising and promotion ......... 102,079 9,487 6,269 -- 117,835
Selling, general and administrative 29,230 15 3,249 -- 32,494
--------- --------- ---------- --------- ---------
Total costs and expenses ........ 201,119 9,502 15,320 -- 225,941
--------- --------- ---------- --------- ---------
INCOME FROM OPERATIONS .............. 79,567 (9,502) 2,136 -- 72,201
--------- --------- ---------- --------- ---------
OTHER INCOME (EXPENSE):
Interest expense .................. (36,572) -- -- -- (36,572)
Investment and other income, net .. 521 (6) 64 -- 579
Royalties ......................... (13,448) 13,743 (295) -- --
Premium revenue ................... (20) -- 20 -- --
Corporate allocations ............. 33 -- (33) -- --
--------- --------- ---------- --------- ---------
Total other income (expense) ... (49,486) 13,737 (244) -- (35,993)
--------- --------- ---------- --------- ---------
INCOME BEFORE INCOME TAXES AND
EXTRAORDINARY LOSS ............. 30,081 4,235 1,892 -- 36,208
PROVISION FOR INCOME TAXES .......... 11,437 1,440 790 -- 13,667
--------- --------- ---------- --------- ---------
INCOME BEFORE EXTRAORDINARY
LOSS ........................... 18,644 2,795 1,102 -- 22,541
EXTRAORDINARY LOSS ON EARLY
EXTINGUISHMENT OF DEBT, NET..... (2,385) -- -- -- (2,385)
--------- --------- ---------- --------- ---------
NET INCOME .......................... $ 16,259 $ 2,795 $ 1,102 $ -- $ 20,156
========= ========= ========= ========= =========
64
Note 16
CHATTEM, INC. AND SUBSIDIARIES
CONSOLIDATING STATEMENTS OF INCOME
FOR THE YEAR ENDED NOVEMBER 30, 1998
(Unaudited and in thousands)
NON-GUARANTOR
SUBSIDIARY ELIMINATIONS
CHATTEM SIGNAL COMPANIES DR, (CR.) CONSOLIDATED
------- ------ --------- ------------ ------------
NET SALES ........................... $ 203,650 $ -- $ 16,414 $ -- $ 220,064
--------- --------- ---------- -------- ---------
COSTS AND EXPENSES:
Cost of sales ..................... 55,654 -- 5,235 -- 60,889
Advertising and promotion ......... 74,462 5,859 6,271 -- 86,592
Selling, general and administrative 24,278 18 3,068 -- 27,364
--------- --------- ---------- -------- ---------
Total costs and expenses ........ 154,394 5,877 14,574 -- 174,845
--------- --------- ---------- -------- ---------
INCOME FROM OPERATIONS .............. 49,256 (5,877) 1,840 -- 45,219
--------- --------- ---------- -------- ---------
OTHER INCOME (EXPENSE):
Interest expense .................. (26,676) -- -- -- (26,676)
Investment and other income, net .. 816 3 62 -- 881
Gain on product divestiture ....... -- 9,548 -- -- 9,548
Royalties ......................... (9,629) 9,891 (262) -- --
Premium revenue ................... (350) -- 350 -- --
Corporate allocations ............. 41 -- (41) -- --
--------- --------- ---------- -------- ---------
Total other income (expense) ... (35,798) 19,442 109 -- (16,247)
--------- --------- ---------- -------- ---------
INCOME BEFORE INCOME TAXES AND
EXTRAORDINARY LOSS .............. 13,458 13,565 1,949 -- 28,972
PROVISION FOR INCOME TAXES .......... 6,000 4,612 232 -- 10,844
--------- --------- ---------- -------- ---------
INCOME BEFORE EXTRAORDINARY
LOSS ............................ 7,458 8,953 1,717 -- 18,128
EXTRAORDINARY LOSS ON EARLY
EXTINGUISHMENT OF DEBT, NET ..... (2,859) -- -- -- (2,859)
--------- --------- ---------- -------- ---------
NET INCOME .......................... $ 4,599 $ 8,953 $ 1,717 $ -- $ 15,269
========= ========= ========= ========= =========
65
Note 16
CHATTEM, INC. AND SUBSIDIARIES
CONSOLIDATING STATEMENTS OF INCOME
FOR THE YEAR ENDED NOVEMBER 30, 1997
(Unaudited and in thousands)
NON-GUARANTOR
SUBSIDIARY ELIMINATIONS
CHATTEM SIGNAL COMPANIES DR, (CR.) CONSOLIDATED
------- ------ --------- ------------ ------------
NET SALES ........................... $ 129,075 $ -- $ 14,160 $ -- $ 143,235
--------- --------- --------- ------- ---------
COSTS AND EXPENSES:
Cost of sales ..................... 35,057 -- 4,196 -- 39,253
Advertising and promotion ......... 48,037 2,627 5,512 -- 56,176
Selling, general and administrative 19,200 27 3,076 -- 22,303
--------- --------- --------- ------- ---------
Total costs and expenses ........ 102,294 2,654 12,784 -- 117,732
--------- --------- --------- ------- ---------
INCOME FROM OPERATIONS .............. 26,781 (2,654) 1,376 -- 25,503
--------- --------- --------- ------- ---------
OTHER INCOME (EXPENSE):
Interest expense .................. (16,319) -- -- -- (16,319)
Intercompany interest ............. 92 -- (92) -- --
Investment and other income, net .. 1,599 31 49 -- 1,679
Royalties ......................... (5,954) 6,181 (227) -- --
Premium revenue ................... (350) -- 350 -- --
Corporate allocations ............. 26 -- (26) -- --
--------- --------- --------- ------- ---------
Total other income (expense) ... (20,906) 6,212 54 -- (14,640)
--------- --------- --------- ------- ---------
INCOME BEFORE INCOME TAXES AND
EXTRAORDINARY LOSS ................ 5,875 3,558 1,430 -- 10,863
PROVISION FOR INCOME TAXES .......... 2,516 1,205 126 -- 3,847
--------- --------- --------- ------- ---------
INCOME BEFORE EXTRAORDINARY
LOSS .............................. 3,359 2,353 1,304 -- 7,016
EXTRAORDINARY LOSS ON EARLY
EXTINGUISHMENT OF DEBT, NET ....... (1,131) -- -- -- (1,131)
--------- --------- --------- ------- ---------
NET INCOME .......................... $ 2,228 $ 2,353 $ 1,304 $ -- $ 5,885
========= ========= ========= ======= =========
66
Note 16
CHATTEM, INC. AND SUBSIDIARIES
CONSOLIDATING STATEMENTS OF CASH FLOWS
FOR THE YEAR ENDED NOVEMBER 30, 1999
(UNAUDITED AND IN THOUSANDS)
NON-GUARANTOR
SUBSIDIARY ELIMINATIONS
CHATTEM SIGNAL COMPANIES DR, (CR.) CONSOLIDATED
------- ------ ------------- ------------ ------------
OPERATING ACTIVITIES:
Net income .......................................... $ 16,259 $ 2,795 $ 1,102 $ -- $ 20,156
Adjustments to reconcile net income to net cash ..... --
provided by operating activities:
Depreciation and amortization ..................... 5,429 9,487 148 -- 15,064
Extraordinary loss on early extinguishment of
debt, net ....................................... 2,385 -- -- -- 2,385
Dividend receivable from Elcat, Inc. .............. (279) -- -- -- (279)
Deferred income tax ............................... 3,158 1,440 -- -- 4,598
Other, net ........................................ (8) 8 -- -- --
Changes in operating assets and liabilities, net of
acquisitions:
Accounts receivable ............................. (16,598) -- (830) -- (17,428)
Inventories ..................................... (5,366) -- 683 -- (4,683)
Prepaid and other current assets ................ (241) -- 82 -- (159)
Accounts payable and accrued liabilities ........ 6,880 -- 388 -- 7,268
--------- --------- --------- --------- ---------
Net cash provided by operating activities .... 11,619 13,730 1,573 -- 26,922
--------- --------- --------- --------- ---------
INVESTING ACTIVITIES:
Purchases of property, plant and equipment .......... (9,789) -- (41) -- (9,830)
Purchases of trademarks and other related assets .... (91,127) -- -- -- (91,127)
Sale of investments ................................. 2,994 387 -- -- 3,381
Proceeds from notes and other assets ................ 272 -- -- 272
Increase in other assets ............................ (3,200) -- -- (3,200)
--------- --------- --------- --------- ---------
Net cash used in investing activities ........ (100,850) 387 (41) -- (100,504)
--------- --------- --------- --------- ---------
FINANCING ACTIVITIES:
Payment of long-term debt ........................... (165,481) -- -- -- (165,481)
Proceeds from long-term debt ........................ 242,281 -- -- -- 242,281
Proceeds from exercise of stock options and
warrants ......................................... 2,104 -- -- -- 2,104
Debt issuance costs ................................. (5,101) -- -- -- (5,101)
Increase in payable to bank ........................ 3,879 -- -- -- 3,879
Changes in intercompany accounts .................... 12,106 (10,112) (1,994) -- --
Dividends paid ...................................... 4,000 (4,000 -- -- --
Repurchases of common stock ......................... (3,912) -- -- (3,912)
--------- --------- --------- --------- ---------
Net cash provided by (used in) financing
activities ............................... 89,876 (14,112) (1,994) -- 73,770
--------- --------- --------- --------- ---------
EFFECT OF EXCHANGE RATE CHANGES ON
CASH AND CASH EQUIVALENTS .......................... -- -- 44 -- 44
--------- --------- --------- --------- ---------
CASH AND CASH EQUIVALENTS:
Increase (decrease) for the period .................. 645 5 (418) -- 232
At beginning of period .............................. (95) 11 2,160 -- 2,076
--------- --------- --------- --------- ---------
At end of period .................................... $ 550 $ 16 $ 1,742 $ -- $ 2,308
========= ========= ========= ========== =========
67
Note 16
CHATTEM, INC. AND SUBSIDIARIES
CONSOLIDATING STATEMENTS OF CASH FLOWS
FOR THE YEAR ENDED NOVEMBER 30, 1998
(UNAUDITED AND IN THOUSANDS)
NON-GUARANTOR
SUBSIDIARY ELIMINATIONS
CHATTEM SIGNAL COMPANIES DR, (CR.) CONSOLIDATED
------- ------ ------------- ------------ ------------
OPERATING ACTIVITIES:
Net income ....................................... $ 4,599 $ 8,953 $ 1,717 $ -- $ 15,269
Adjustments to reconcile net income to net cash
provided by operating activities:
Depreciation and amortization .................. 3,829 5,859 139 -- 9,827
Extraordinary loss on early extinguishment of
debt, net ..................................... 2,859 -- -- -- 2,859
Dividend receivable from Elcat, Inc. ........... (462) -- -- -- (462)
Deferred income tax provision .................. (2,261) 4,612 -- -- 2,351
Gain on product divestiture .................... -- (9,548) -- -- (9,548)
Other, net ..................................... (28) -- -- -- (28)
Changes in operating assets and liabilities, net
of acquisitions:
Accounts receivable .......................... (11,968) -- (86) -- (12,054)
Inventories .................................. 2,570 -- (734) -- 1,836
Prepaid and other current assets ............. 80 -- (182) -- (102)
Accounts payable and accrued liabilities ..... 10,482 -- 360 -- 10,842
--------- --------- --------- ----- ---------
Net cash provided by operating activities . 9,700 9,876 1,214 -- 20,790
--------- --------- --------- ----- ---------
INVESTING ACTIVITIES:
Purchases of property, plant and equipment ....... (8,988) -- (62) -- (9,050)
Purchases of trademarks and other related assets . (168,402) -- -- -- (168,402)
Proceeds from sale of investments ................ 4,000 -- -- -- 4,000
Proceeds from product divestiture ................ 11,965 -- -- -- 11,965
Proceeds form notes and sales of assets .......... 1,085 -- -- -- 1,085
Increases in other assets ........................ (798) (395) -- -- (1,193)
--------- --------- --------- ----- ---------
Net cash used in investing activities ..... (161,138) (395) (62) -- (161,595)
--------- --------- --------- ----- ---------
FINANCING ACTIVITIES:
Repayment of long-term debt ...................... (145,028) -- -- -- (145,028)
Proceeds from long-term debt ..................... 291,365 -- -- -- 291,365
Proceeds from exercise of stock options and
warrants ....................................... 3,316 -- -- -- 3,316
Debt issuance costs .............................. (9,971) -- -- -- (9,971)
Decrease in payable to bank ...................... (1,592) -- -- -- (1,592)
Changes in intercompany accounts ................. 6,259 (5,525) (734) -- --
Dividends paid ................................... 4,000 (4,000) -- -- --
--------- --------- --------- ----- ---------
Net cash provided by (used in)financing
activities ............................... 148,349 (9,525) (734) -- 138,090
--------- --------- --------- ----- ---------
EFFECT OF EXCHANGE RATE CHANGES ON
CASH AND CASH EQUIVALENTS ........................ (2) -- (65) -- (67)
--------- --------- --------- ----- ---------
CASH AND CASH EQUIVALENTS:
Increase (decrease) for the period ............... (3,091) (44) 353 -- (2,782)
At beginning of period ........................... 2,996 55 1,807 -- 4,858
--------- --------- --------- ----- ---------
At end of period ................................. $ (95) $ 11 $ 2,160 $ -- $ 2,076
========= ========= ========= ====== =========
68
Note 16
CHATTEM, INC. AND SUBSIDIARIES
CONSOLIDATING STATEMENTS OF CASH FLOWS
FOR THE YEAR ENDED NOVEMBER 30, 1997
(UNAUDITED AND IN THOUSANDS)
NON-GUARANTOR
SUBSIDIARY ELIMINATIONS
CHATTEM SIGNAL COMPANIES DR, (CR.) CONSOLIDATED
------- ------ ------------- ------------ ------------
OPERATING ACTIVITIES:
Net income .......................................... $ 2,228 $ 2,353 $ 1,304 $ -- $ 5,885
Adjustments to reconcile net income to net cash
provided by operating activities:
Depreciation and amortization ..................... 3,606 2,627 148 -- 6,381
Extraordinary loss on early extinguishment of
debt, net ....................................... 1,131 -- -- -- 1,131
Dividend receivable from Elcat, Inc. .............. (656) -- -- -- (656)
Deferred income tax provision ..................... (231) 1,205 -- -- 974
Other, net ........................................ (119) 10 3 -- (106)
Changes in operating assets and liabilities, net of
acquisitions:
Accounts receivable ............................. (5,296) -- 156 -- (5,140)
Inventories ..................................... (1,974) -- (427) -- (2,401)
Prepaid and other current assets ................ 2,962 -- 72 -- 3,034
Accounts payable and accrued liabilities ........ 1,096 -- (82) -- 1,014
-------- -------- -------- -------- --------
Net cash provided by operating activities ..... 2,747 6,195 1,174 -- 10,116
-------- -------- -------- -------- --------
INVESTING ACTIVITIES:
Purchases of property, plant and equipment .......... (2,441) -- (317) -- (2,758)
Purchases of trademarks and other related assets .... (29,293) -- -- -- (29,293)
Proceeds from notes and other assets ................ 75 -- -- -- 75
Increase in other assets ........................... (746) -- -- -- (746)
-------- -------- -------- -------- --------
Net cash used in investing activities ......... (32,405) -- (317) -- (32,722)
-------- -------- -------- -------- --------
FINANCING ACTIVITIES:
Repayment of long-term debt ......................... (76,636) -- -- -- (76,636)
Proceeds from long-term debt ........................ 87,500 -- -- -- 87,500
Proceeds from exercise of stock options and
warrants .......................................... 1,274 -- -- -- 1,274
Debt issuance costs ................................. (1,612) -- -- -- (1,612)
Increase in payable to bank ........................ 908 -- -- -- 908
Changes in intercompany accounts .................... 2,584 (3,551) 967 -- --
Dividends paid ...................................... 5,500 (5,500) -- -- --
Payment of intercompany notes ....................... 2,679 (2,679) --
-------- -------- -------- -------- --------
Net cash provided by (used in) financing
activities ................................. 22,197 (9,051) (1,712) -- 11,434
-------- -------- -------- -------- --------
EFFECT OF EXCHANGE RATE CHANGES ON CASH
AND CASH EQUIVALENTS .................................. -- -- (10) -- (10)
-------- -------- -------- -------- --------
CASH AND CASH EQUIVALENTS:
Increase (decrease) for the period .................. (7,461) (2,856) (865) -- (11,182)
At beginning of period .............................. 10,457 2,911 2,672 -- 16,040
-------- -------- -------- -------- --------
At end of period .................................... $ 2,996 $ 55 $ 1,807 $ -- $ 4,858
======== ======== ======== ======== ========
69
(17) QUARTERLY INFORMATION (Unaudited and in thousands, except per share
amounts)
QUARTER ENDED
------------------------------------------------------
TOTAL FEBRUARY 28 MAY 31 AUGUST 31 NOVEMBER 30
----- ----------- ------ --------- -----------
FISCAL 1999:
Net sales .......................... $ 298,142 62,728 83,441 78,661 73,312
Gross profit ....................... $ 222,530 45,848 61,647 57,616 57,419
Before extraordinary loss:
Income ........................... $ 22,541 3,577 6,921 5,957 6,086
Income per share,
diluted(2)....................... $ 2.25 .35 .69 .59 .61
Total:
Net income ....................... $ 20,156 3,150 5,764 5,424 5,818
Net income per share,
diluted(2) ..................... $ 2.01 .31 .57 .54 .58
FISCAL 1998:
Net sales .......................... $ 220,064 34,921 58,545 67,600 58,998
Gross profit ....................... $ 159,175 25,239 42,691 48,219 43,026
Before extraordinary loss:
Income (1) ....................... $ 18,128 609 10,069 4,391 3,059
Income per share, diluted (1), (2) $ 1.86 .06 1.02 .45 .31
Total:
Net income (1) ................... $ 15,269 609 8,168 3,433 3,059
Net income per share,
diluted (1),(2) ................ $ 1.57 .06 .83 .35 .31
(1) INCLUDES THE EFFECT OF THE DIVESTITURE OF CORNSILK.
(2) THE SUM OF THE QUARTERLY EARNINGS PER SHARE AMOUNTS MAY DIFFER
FROM ANNUAL EARNINGS PER SHARE BECAUSE OF THE DIFFERENCES IN THE
WEIGHTED AVERAGE NUMBER OF COMMON SHARES AND DILUTIVE POTENTIAL
SHARES USED IN THE QUARTERLY AND ANNUAL COMPUTATIONS.
70
REPORT OF INDEPENDENT
PUBLIC ACCOUNTANTS
TO CHATTEM, INC.:
We have audited the accompanying consolidated balance sheets of Chattem, Inc.
(a Tennessee corporation) and subsidiaries as of November 30, 1999 and 1998
and the related consolidated statements of income, shareholders' equity and
cash flows for the years ended November 30, 1999, 1998 and 1997 (as revised, -
see Note 2). These financial statements are the responsibility of the
Company's management. Our responsibility is to express an opinion on these
financial statements based on our audits.
We conducted our audits in accordance with auditing standards generally accepted
in the United States. Those standards require that we plan and perform the audit
to obtain reasonable assurance about whether the financial statements are free
of material misstatement. An audit includes examining, on a test basis, evidence
supporting the amounts and disclosures in the financial statements. An audit
also includes assessing the accounting principles used and significant estimates
made by management, as well as evaluating the overall financial statement
presentation. We believe that our audits provide a reasonable basis for our
opinion.
In our opinion, the financial statements referred to above present fairly, in
all material respects, the financial position of Chattem, Inc. and subsidiaries
as of November 30, 1999 and 1998, and the results of their operations and their
cash flows for each of the three years in the period ended November 30, 1999 in
conformity with accounting principles generally accepted in the United States.
ARTHUR ANDERSEN LLP
Chattanooga, Tennessee
January 27, 2000
71